{"id":"amiodarone","rwe":[{"pmid":"41901253","year":"2026","title":"A Simple Dual-Track HPLC-UV Methodology for Monitoring Primary Antiarrhythmic Drugs and Their Active Metabolites in Serum.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41896159","year":"2026","title":"Drug-associated torsades de pointes and QT prolongation in infants: A focused real-world disproportionality analysis pharmacovigilance study.","finding":"","journal":"Pediatrics and neonatology","studyType":"Clinical Study"},{"pmid":"41892494","year":"2026","title":"Thyroid Monitoring and Amiodarone-Induced Thyroid Disease in Australian General Practice: A Retrospective Cohort Study.","finding":"","journal":"Clinics and practice","studyType":"Clinical Study"},{"pmid":"41884902","year":"2026","title":"Rapid Atrial Pacing-Induced Wenckebach Atrioventricular Block: A Poor Predictor of Permanent Pacemaker Need Post-TAVR.","finding":"","journal":"Circulation. Cardiovascular interventions","studyType":"Clinical Study"},{"pmid":"41884060","year":"2026","title":"Short- to mid-term outcomes of refractory electrical storm patients listed for urgent heart transplantation.","finding":"","journal":"JHLT open","studyType":"Clinical Study"}],"_fda":{"id":"f373ed89-c786-4f7c-a55e-2d1dc62971b0","set_id":"02f4a736-63ed-4ad4-a1f1-b21a71e928bd","openfda":{"unii":["976728SY6Z"],"route":["ORAL"],"rxcui":["833528","834346"],"spl_id":["f373ed89-c786-4f7c-a55e-2d1dc62971b0"],"brand_name":["Pacerone"],"spl_set_id":["02f4a736-63ed-4ad4-a1f1-b21a71e928bd"],"package_ndc":["71610-787-30"],"product_ndc":["71610-787"],"generic_name":["AMIODARONE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AMIODARONE HYDROCHLORIDE"],"manufacturer_name":["Aphena Pharma Solutions - Tennessee, LLC"],"application_number":["ANDA075135"],"original_packager_product_ndc":["0245-0147"]},"version":"1","pregnancy":["8.1 Pregnancy Risk Summary Available data from post-marketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. Amiodarone and its metabolite, desethylamiodarone (DEA), cross the placenta. Untreated underlying arrhythmias, including ventricular arrhythmias, during pregnancy pose a risk to the mother and fetus (see Clinical Considerations ) . In animal studies, administration of amiodarone to rabbits, rats, and mice during organogenesis resulted in embryo-fetal toxicity at doses less than the maximum recommended human maintenance dose (see Data ) . Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk The incidence of ventricular tachycardia is increased and may be more symptomatic during pregnancy. Ventricular arrhythmias most often occur in pregnant women with underlying cardiomyopathy, congenital heart disease, valvular heart disease, or mitral valve prolapse. Most tachycardia episodes are initiated by ectopic beats and the occurrence of arrhythmia episodes may, therefore, increase during pregnancy due to the increased propensity to ectopic activity. Breakthrough arrhythmias may also occur during pregnancy, as therapeutic treatment levels may be difficult to maintain due to the increased volume of distribution and increased drug metabolism inherent in the pregnant state. Fetal/Neonatal adverse reactions Amiodarone and its metabolite have been shown to cross the placenta. Adverse fetal effects associated with maternal amiodarone use during pregnancy may include neonatal bradycardia, QT prolongation, and periodic ventricular extrasystoles, neonatal hypothyroidism (with or without goiter) detected antenatally or in the newborn and reported even after a few days of exposure, neonatal hyperthyroxinemia, neurodevelopmental abnormalities independent of thyroid function, including speech delay and difficulties with written language and arithmetic, delayed motor development, and ataxia, jerk nystagmus with synchronous head titubation, fetal growth restriction, and premature birth. Monitor the newborn for signs and symptoms of thyroid disorder and cardiac arrhythmias. Labor and Delivery Risk of arrhythmias may increase during labor and delivery. Patients treated with Pacerone should be monitored continuously during labor and delivery [see Warnings and Precautions (5.4) ] . Data Animal Data In pregnant rats and rabbits during the period of organogenesis, amiodarone hydrochloride in doses of 25 mg/kg/day (approximately 0.4 and 0.9 times, respectively, the maximum recommended human maintenance dose 600 mg in a 60 kg patient (doses compared on a body surface area basis) ) had no adverse effects on the fetus. In the rabbit, 75 mg/kg/day (approximately 2.7 times the maximum recommended human maintenance dose ) caused abortions in greater than 90% of the animals. In the rat, doses of 50 mg/kg/day or more were associated with slight displacement of the testes and an increased incidence of incomplete ossification of some skull and digital bones; at 100 mg/kg/day or more, fetal body weights were reduced; at 200 mg/kg/day, there was an increased incidence of fetal resorption. (These doses in the rat are approximately 0.8, 1.6 and 3.2 times the maximum recommended human maintenance dose ) Adverse effects on fetal growth and survival also were noted in one of two strains of mice at a dose of 5 mg/kg/day (approximately 0.04 times the maximum recommended human maintenance dose )."],"overdosage":["10 OVERDOSAGE There have been cases, some fatal, of amiodarone hydrochloride overdose. Monitor the patient's cardiac rhythm and blood pressure, and, if bradycardia ensues, a β-adrenergic agonist or a pacemaker may be used. Treat hypotension with inadequate tissue perfusion with positive inotropic and vasopressor agents. Neither Pacerone nor its metabolite is dialyzable."],"description":["11 DESCRIPTION Pacerone (amiodarone hydrochloride tablets, USP) are an antiarrhythmic drug, available for oral administration as 100 mg; peach tablets, 200 mg; pink tablets and 400 mg; white tablets containing amiodarone hydrochloride, USP. All three strengths of Pacerone tablets contain the following inactive ingredients: lactose monohydrate, magnesium stearate, povidone, pregelatinized corn starch, sodium starch glycolate and stearic acid. The 200 mg tablets also contain FD&C Red No. 40 and FD&C Yellow No. 6. The 100 mg tablets also contain FD&C Yellow No. 6. Amiodarone hydrochloride, USP is a benzofuran derivative: 2-butyl-3-benzofuranyl 4-[2-(diethylamino)-ethoxy]-3,5-diiodophenyl ketone hydrochloride. The structural formula is as follows: C 25 H 29 I 2 NO 3 ∙ HCl Molecular Weight: 681.8 C 25 H 29 I 2 NO 3 ∙ HCl Molecular Weight: 681.8 Amiodarone hydrochloride, USP is a white to cream-colored crystalline powder. It is slightly soluble in water, soluble in alcohol, and freely soluble in chloroform. It contains 37.3% iodine by weight. Meets USP Dissolution Test 4. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Pacerone ® (amiodarone hydrochloride tablets, USP) 100 mg are peach, round, flat-faced, uncoated tablets, debossed with \"P\" on one side, and \"U-S\" above \"144\" on the other side. They are supplied as follows: Bottles of 30 with child-resistant closure, NDC 0245-0144-30 Bottles of 100 with child-resistant closure, NDC 0245-0144-11 Unit-dose cartons of 100 tablets, NDC 0245-0144-01 Pacerone ® (amiodarone hydrochloride tablets, USP) 200 mg, are pink, round, flat-faced, scored, uncoated tablets, debossed with \"P 200 \" on the unscored side, and \"U-S\" above and \"0147\" below the score on the reverse side. They are supplied as follows: Bottles of 60 with child-resistant closure, NDC 0245-0147-60 Bottles of 90 with child-resistant closure, NDC 0245-0147-90 Bottles of 500 tablets, NDC 0245-0147-15 Unit-dose cartons of 100 tablets, NDC 0245-0147-01 Pacerone ® (amiodarone hydrochloride tablets, USP) 400 mg, are white to off-white, round, uncoated, scored tablets, debossed with \"U-S\" above and \"1645\" below the score on one side and \"P 400 \" on the unscored side. They are supplied as follows: Bottles of 30 with child-resistant closure, NDC 0245-1645-30 Unit-dose cartons of 100 tablets, NDC 0245-1645-01 Keep tightly closed. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container with a child-resistant closure."],"spl_medguide":["MEDICATION GUIDE Pacerone ® (PĀS-ər-ōn) Tablets (Amiodarone Hydrochloride) What is the most important information I should know about Pacerone tablets? Pacerone tablets can cause serious side effects that can lead to death, including: lung problems liver problems worsening of heartbeat problems Call your healthcare provider or get medical help right away if you have any of the following symptoms during treatment with Pacerone tablets: trouble breathing, wheezing, shortness of breath, coughing chest pain, spitting up of blood, or fever nausea or vomiting, brown or dark-colored urine, feel more tired than usual, yellowing of your skin or the whites of your eyes (jaundice), or right upper stomach-area pain heart pounding, skipping a beat, beating fast or slowly, feel light-headed, or if you faint vision problems, including blurred vision, see halos, or your eyes become sensitive to light. You should have regular eye exams before and during treatment with Pacerone tablets. Pacerone tablets should be started in a hospital so that your medical condition can be carefully monitored. Pacerone tablets should only be used to treat people who have been diagnosed with life-threatening heartbeat problems called ventricular arrhythmias, when other treatments did not work or you cannot tolerate them. Pacerone tablets can cause other serious side effects. See \" What are the possible side effects of Pacerone tablets? \" If you get serious side effects during treatment you may need to stop Pacerone tablets, have your dose changed, or get medical treatment. Talk with your healthcare provider before you stop taking Pacerone tablets. You may still have side effects after stopping Pacerone tablets because the medicine stays in your body for months after treatment is stopped. You should have regular check-ups, blood tests, chest x-rays before and during treatment with Pacerone tablets to check for serious side effects. You should also have lung function tests before starting treatment with Pacerone tablets. What are Pacerone tablets? Pacerone tablets are a prescription medicine used to treat people who have been diagnosed with life-threatening heartbeat problems called ventricular arrhythmias, when other treatments did not work or you cannot tolerate them. It is not known if Pacerone tablets are safe and effective in children. Who should not take Pacerone tablets? Do not take Pacerone tablets if you: have a serious heart problem called cardiogenic shock have certain types of the heart condition called heart block, with or without a slow heart rate have a slow heart rate with dizziness or lightheadedness, and you do not have an implanted pacemaker are allergic to amiodarone, iodine, or any of the other ingredients in Pacerone tablets. See the end of this Medication Guide for a complete list of ingredients in Pacerone tablets. Before taking Pacerone tablets, tell your healthcare provider about all of your medical conditions, including if you: have lung or breathing problems have liver problems have or had thyroid problems have a slow heart rate or blood pressure problems have diarrhea or have had diarrhea for a long period of time have been told that you have low levels of potassium, magnesium, or calcium in your blood have an implanted pacemaker or defibrillator if you plan to have surgery with general anesthesia are pregnant or plan to become pregnant. Pacerone tablets may harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with Pacerone tablets. Pacerone can stay in your body for months after treatment is stopped. are breastfeeding or plan to breastfeed. Pacerone can pass into your breast milk and may harm your baby. You should not breast feed while taking Pacerone tablets. Pacerone can stay in your body for months after treatment is stopped. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Pacerone tablets and certain other medicines can affect with each other and cause serious side effects. You can ask your pharmacist for a list of medicines that interact with Pacerone tablets. How should I take Pacerone tablets? When you are discharged from the hospital, take Pacerone tablets exactly as your doctor tells you to take it. Your healthcare provider will tell you how much Pacerone to take and when to take it. Your healthcare provider may change your dose of Pacerone as needed if your heart rhythm is controlled, or if you have certain side effects. Your healthcare provider should monitor you carefully when your dose of Pacerone is being changed. Take your dose of Pacerone tablets the same way each time, either with or without food. If you take too much Pacerone, call your healthcare provider or go to the nearest hospital emergency room right away. If you miss a dose, wait and take your next dose at your regular time. Do not take two doses at the same time. Continue with your next regularly scheduled dose. What should I avoid while taking Pacerone tablets? Avoid drinking grapefruit juice during treatment with Pacerone. Drinking grapefruit juice with Pacerone tablets may increase the amount of Pacerone in your blood, and this may lead to side effects. Pacerone tablets can make your skin sensitive to sunlight. You could get severe sunburn. Use sunscreen and wear a hat and clothes that cover your skin to help protect you if you must be in sunlight. Talk to your healthcare if you get a sunburn. See \" Skin problems \" in the Medication Guide section \"What are the possible side effects of Pacerone tablets?\" below. What are the possible side effects of Pacerone tablets? Pacerone tablets can cause serious side effects, including: See \" What is the most important information I should know about Pacerone tablets? \" Nerve problems . Pacerone tablets can cause nerve problems. Call your healthcare provider if you develop symptoms of nerve problems, including: a feeling of \"pins and needles\" or numbness in your hands, legs, or feet, muscle weakness, uncontrolled movements, poor coordination, or trouble walking. Skin problems . Pacerone tablets can cause your skin to be more sensitive to the sun or turn a bluish-gray color. People who have fair skin or people who have a lot of sun exposure may be more at risk for these skin problems. Some of the bluish-gray skin color may return to normal after stopping Pacerone tablets. Thyroid problems. Pacerone tablets can cause you to have either decreased thyroid function (hypothyroidism), which can sometimes be severe, or an overactive thyroid (hyperthyroidism), which can be severe. If you develop decreased thyroid function during treatment with Pacerone tablets, your healthcare provider may need to reduce your dose or stop your treatment with Pacerone tablets, and possibly prescribe medicine to replace your thyroid hormone. An overactive thyroid can cause you to produce too much thyroid hormone. You can have abnormal heartbeats even while you are receiving Pacerone tablets. Your healthcare provider may prescribe certain medicines to treat your overactive thyroid. Call your healthcare provider if you get any abnormal heartbeats during treatment with Pacerone tablets. This may mean that you have an overactive thyroid. Your healthcare provider should do tests to check your thyroid function before you start and during treatment with Pacerone tablets. Call your healthcare provider if you develop any of the following symptoms of a thyroid problem during treatment with Pacerone tablets: weakness weight loss or weight gain heat or cold intolerance hair thinning sweating changes in your menstrual periods swelling of your neck (goiter) nervousness irritability restlessness decreased concentration feeling depressed (in the elderly) tremor The most common side effects of Pacerone tablets include: lung problems heartbeat problems heart problems liver problems Pacerone tablets may affect fertility in males and females. It is not known if the effects are reversible. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of Pacerone tablets. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Pacerone tablets? Store Pacerone tablets at room temperature between 20° to 25°C (68° to 77°F). Keep Pacerone tablets in a tightly closed container and keep Pacerone tablets out of the light. Pacerone comes in a child-resistant package. Keep Pacerone tablets and all medicines out of the reach of children. General information about the safe and effective use of Pacerone tablets Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Pacerone tablets for a condition for which it was not prescribed. Do not give Pacerone tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Pacerone tablets that is written for health professionals. What are the ingredients in Pacerone tablets? Active Ingredient : amiodarone hydrochloride Inactive Ingredients : lactose monohydrate, magnesium stearate, povidone, pregelatinized corn starch, sodium starch glycolate, stearic acid, FD&C Red No. 40 (200 mg) and FD&C Yellow No. 6 (100 mg and 200 mg). For more information and the most current Medication Guide, please visit www.upsher-smith.com or call 1-888-650-3789. This Medication Guide has been approved by the U.S. Food and Drug Administration. Manufactured by UPSHER-SMITH LABORATORIES, LLC Maple Grove, MN 55369 Pacerone is a registered trademark of Upsher-Smith Laboratories, LLC. Revised 5/2020"],"boxed_warning":["WARNING: PULMONARY, HEPATIC and CARDIAC TOXICITY Pacerone is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity [see Indications and Usage (1) ] . Pacerone can cause pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 17% in some series of patients. Pulmonary toxicity has been fatal about 10% of the time . Obtain a baseline chest X-ray and pulmonary-function tests, including diffusion capacity, when Pacerone therapy is initiated. Repeat history, physical exam, and chest X-ray every 3 to 6 months [see Warnings and Precautions 5.2) ] . Pacerone can cause hepatoxicity, which can be fatal. Obtain baseline and periodic liver transaminases and discontinue or reduce dose if the increase exceeds three times normal, or doubles in a patient with an elevated baseline. Discontinue Pacerone if the patient experiences signs or symptoms of clinical liver injury [see Warnings and Precautions (5.3) ] . Pacerone can exacerbate arrhythmias. Initiate amiodarone hydrochloride in a clinical setting where continuous electrocardiograms and cardiac resuscitation are available [see Warnings and Precautions (5.4) ] . WARNING: PULMONARY, HEPATIC, and CARDIAC TOXICITY See full prescribing information for complete boxed warning. Reserve Pacerone for patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity, some also life-threatening. Utilize alternative agents first. ( 1 ) Pacerone' s life-threatening toxicities include pulmonary ( 5.2 ), hepatic ( 5.3 ), and proarrhythmic ( 5.4 ). Initiate under hospital or specialist supervision. ( 5 )"],"geriatric_use":["8.5 Geriatric Use Normal subjects over 65 years of age show lower clearances and increased drug half-life than younger subjects [see Clinical Pharmacology (12.3) ] . In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Pacerone in pediatric patients have not been established."],"effective_time":"20240202","pharmacodynamics":["12.2 Pharmacodynamics There is no well-established relationship between plasma concentration and effectiveness, but it does appear that concentrations much below 1 mg/L are often ineffective and that levels above 2.5 mg/L are generally not needed. Plasma-concentration measurements can be used to identify patients whose levels are unusually low, and who might benefit from a dose increase, or unusually high, and who might have dosage reduction in the hope of minimizing side effects. Effects on abnormal rhythms are not seen before 2 to 3 days and usually require 1 to 3 weeks, even when a loading dose is used. There may be a continued increase in effect for longer periods still. There is evidence that the time to effect is shorter when a loading-dose regimen is used. Consistent with the slow rate of elimination, antiarrhythmic effects persist for weeks or months after amiodarone hydrochloride is discontinued, but the time of recurrence is variable and unpredictable. In general, when the drug is resumed after recurrence of the arrhythmia, control is established relatively rapidly compared to the initial response, presumably because tissue stores were not wholly depleted."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Following oral administration in humans, amiodarone hydrochloride is slowly and variably absorbed. The bioavailability of amiodarone hydrochloride is approximately 50%. Maximum plasma concentrations are attained 3 to 7 hours after a single dose. Plasma concentrations with chronic dosing at 100 to 600 mg/day are approximately dose proportional, with a mean 0.5 mg/L increase for each 100 mg/day. These means, however, include considerable individual variability. Food increases the rate and extent of absorption of amiodarone hydrochloride. The effects of food upon the bioavailability of amiodarone hydrochloride have been studied in 30 healthy subjects who received a single 600-mg dose immediately after consuming a high-fat meal and following an overnight fast. The area under the plasma concentration-time curve (AUC) and the peak plasma concentration (C max ) of amiodarone increased by 2.3 (range 1.7 to 3.6) and 3.8 (range 2.7 to 4.4) times, respectively, in the presence of food. Food also increased the rate of absorption of amiodarone, decreasing the time to peak plasma concentration (T max ) by 37%. The mean AUC and mean C max of the major metabolite of amiodarone, DEA increased by 55% (range 58% to 101%) and 32% (range 4% to 84%), respectively, but there was no change in the T max in the presence of food. Distribution Pacerone is highly protein-bound (approximately 96%). Pacerone has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen. One major metabolite of amiodarone hydrochloride, DEA, has been identified in man; it accumulates to an even greater extent in almost all tissues. No data are available on the activity of DEA in humans, but in animals, it has significant electrophysiologic and antiarrhythmic effects generally similar to amiodarone itself. DEA's precise role and contribution to the antiarrhythmic activity of oral amiodarone are not certain. The development of maximal ventricular class III effects after oral amiodarone hydrochloride administration in humans correlates more closely with DEA accumulation over time than with amiodarone accumulation. Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA). In patients, following discontinuation of chronic oral therapy, amiodarone hydrochloride has been shown to have a biphasic elimination with an initial 50% reduction of plasma levels after 2.5 to 10 days. A much slower terminal plasma-elimination phase shows a half-life of the parent compound ranging from 26 to 107 days, with a mean of approximately 53 days and most patients in the 40- to 55-day range. In the absence of a loading-dose period, steady-state plasma concentrations, at constant oral dosing, would therefore be reached between 130 and 535 days, with an average of 265 days. For the metabolite, the mean plasma-elimination half-life was approximately 61 days. These data probably reflect an initial elimination of drug from well-perfused tissue (the 2.5- to 10-day half-life phase), followed by a terminal phase representing extremely slow elimination from poorly perfused tissue compartments such as fat. The considerable inter-subject variation in both phases of elimination, as well as uncertainty as to what compartment is critical to drug effect, requires attention to individual responses once arrhythmia control is achieved with loading doses because the correct maintenance dose is determined, in part, by the elimination rates. Individualize maintenance doses of Pacerone tablets [see Dosage and Administration (2) ] . Metabolism Amiodarone is metabolized to DEA by the cytochrome P450 (CYP) enzyme group, specifically CYP3A and CYP2C8. The CYP3A isoenzyme is present in both the liver and intestines. In vitro , amiodarone and DEA exhibit a potential to inhibit CYP2C9, CYP2C19, CYP2D6, CYP3A, CYP2A6, CYP2B6 and CYP2C8. Amiodarone and DEA have also a potential to inhibit some transporters such as P-glycoprotein and organic cation transporter (OCT2). Excretion Amiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine. Neither amiodarone nor DEA is dialyzable. Specific Populations Effect of Age: Normal subjects over 65 years of age show lower clearances (about 100 mL/hr/kg) than younger subjects (about 150 mL/hr/kg) and an increase in t½ from about 20 to 47 days. Renal Impairment: Renal impairment does not influence the pharmacokinetics of amiodarone or DEA. Hepatic Impairment: After a single dose of intravenous amiodarone to cirrhotic patients, significantly lower C max and average concentration values are seen for DEA, but mean amiodarone levels are unchanged. Cardiac Disease: In patients with severe left ventricular dysfunction, the pharmacokinetics of amiodarone are not significantly altered but the terminal elimination t½ of DEA is prolonged. Although no dosage adjustment for patients with renal, hepatic, or cardiac abnormalities has been defined during chronic treatment with oral amiodarone, close clinical monitoring is prudent for elderly patients and those with severe left ventricular dysfunction. Drug Interactions: Effects of other agents on amiodarone Grapefruit juice: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and C max by 84%, and decreased DEA to unquantifiable concentrations. Cimetidine inhibits CYP3A and can increase serum amiodarone levels. Cholestyramine reduces enterohepatic circulation of amiodarone thereby increasing its elimination. This results in reduced amiodarone serum levels and half-life. Effects of amiodarone on agents CYP3A substrates: Amiodarone taken concomitantly with quinidine increases the quinidine serum concentration by 33% after two days. Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. Loratadine , a non-sedating antihistaminic, is metabolized primarily by CYP3A and its metabolism can be inhibited by amiodarone. Metabolism of lidocaine can be inhibited by amiodarone. Cyclophosphamide is a prodrug, metabolized by CYP450 including CYP3A to an active metabolite. The metabolism of cyclophosphamide may be inhibited by amiodarone. Clopidogrel , an inactive thienopyridine prodrug, is metabolized in the liver by CYP3A to an active metabolite. A potential interaction between clopidogrel and amiodarone resulting in ineffective inhibition of platelet aggregation has been reported. Macrolide/ketolide antibiotics: Amiodarone can inhibit the metabolism of macrolide/ketolide antibiotics (except for azithromycin) and systemic azole antifungal drugs. P-glycoprotein substrates: Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. Dabigatran etexilate when taken concomitantly with oral amiodarone can result in elevated serum concentration of dabigatran. Dextromethorphan is a substrate for both CYP2D6 and CYP3A. Amiodarone inhibits CYP2D6. Chronic (>2 weeks) oral amiodarone administration impairs metabolism of dextromethorphan can lead to increased serum concentrations."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are described in more detail in other sections of the prescribing information: Pulmonary Toxicity [see Warnings and Precautions (5.2) ] Hepatic Injury [see Warnings and Precautions (5.3) ] Worsened Arrhythmia [see Warnings and Precautions (5.4) ] Visual Impairment and Loss of Vision [see Warnings and Precautions (5.5) ] Thyroid Abnormalities [see Warnings and Precautions (5.6) ] Bradycardia [see Warnings and Precautions (5.7) ] Peripheral Neuropathy [see Warnings and Precautions (5.10) ] Photosensitivity and Skin Discoloration [see Warnings and Precautions (5.11) ] The most common reactions (>1%) leading to discontinuation of amiodarone include pulmonary toxicity, paroxysmal ventricular tachycardia, congestive heart failure, and elevation of liver enzymes. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Upsher-Smith Laboratories, LLC at 1-855-899-9180 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. At the usual maintenance dose (400 mg/day) and above, amiodarone hydrochloride causes adverse reactions in about three-fourths of all patients, resulting in discontinuation in 7% to 18%. In surveys of almost 5,000 patients treated in open U.S. studies and in published reports of treatment with amiodarone hydrochloride, the adverse reactions most frequently requiring discontinuation of amiodarone hydrochloride included pulmonary infiltrates or fibrosis, paroxysmal ventricular tachycardia, congestive heart failure, and elevation of liver enzymes. Other symptoms causing discontinuations less often included visual disturbances, photosensitivity, blue skin discoloration, hyperthyroidism, and hypothyroidism. The following side-effect rates are based on a retrospective study of 241 patients treated for 2 to 1,515 days (mean 441.3 days): Thyroid Common: Hypothyroidism, hyperthyroidism. Cardiovascular Common: Congestive heart failure, cardiac arrhythmias, SA node dysfunction. Gastrointestinal Very common: Nausea, vomiting. Common: Constipation, anorexia, abdominal pain. Dermatologic Common: Solar dermatitis/photosensitivity. Neurologic Common: Malaise and fatigue, tremor/abnormal involuntary movements, lack of coordination, abnormal gait/ataxia, dizziness, paresthesias, decreased libido, insomnia, headache, sleep disturbances. Ophthalmic Common: Visual disturbances. Hepatic Common: Abnormal liver-function tests, nonspecific hepatic disorders. Respiratory Common: Pulmonary inflammation or fibrosis. Other Common: Flushing, abnormal taste and smell, edema, abnormal salivation, coagulation abnormalities. Uncommon: Blue skin discoloration, rash, spontaneous ecchymosis, alopecia, hypotension, and cardiac conduction abnormalities. 6.2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of amiodarone hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hematologic: hemolytic anemia, aplastic anemia, pancytopenia, neutropenia, thrombocytopenia, agranulocytosis, granuloma. Immune: anaphylactic/anaphylactoid reaction (including shock), angioedema. Neurologic: pseudotumor cerebri, parkinsonian symptoms such as akinesia and bradykinesia (sometimes reversible with discontinuation of therapy), demyelinating polyneuropathy. Psychiatric: hallucination, confusional state, disorientation, delirium. Cardiac: hypotension (sometimes fatal), sinus arrest. Respiratory: eosinophilic pneumonia, acute respiratory distress syndrome in the post-operative setting, bronchospasm, bronchiolitis obliterans organizing pneumonia, pulmonary alveolar hemorrhage, pleural effusion, pleuritis. Gastrointestinal: pancreatitis, acute pancreatitis. Hepatic: hepatitis, cholestatic hepatitis, cirrhosis. Skin and Subcutaneous Tissue Disorders: urticaria, toxic epidermal necrolysis (sometimes fatal), erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, bullous dermatitis, drug rash with eosinophilia and systemic symptoms (DRESS), eczema, pruritus, skin cancer, lupus-like syndrome. Musculoskeletal: myopathy, muscle weakness, rhabdomyolysis. Renal: renal impairment, renal insufficiency, acute renal failure. Reproductive: epididymitis, impotence. Body as a whole: fever, dry mouth. Endocrine and metabolic: thyroid nodules/ thyroid cancer, syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vascular: vasculitis."],"contraindications":["4 CONTRAINDICATIONS Cardiogenic shock. Sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia leading to syncope without a functioning pacemaker. Known hypersensitivity to the drug or to any of its components, including iodine. Pacerone is contraindicated in patients with ( 4 ): Cardiogenic shock. Sick sinus syndrome, second- or third-degree AV block, bradycardia leading to syncope without a functioning pacemaker. Known hypersensitivity to the drug or any of its components."],"drug_interactions":["7 DRUG INTERACTIONS Because of amiodarone's long half-life, expect drug interactions to persist for weeks to months after discontinuation of amiodarone. Drug interactions with amiodarone are described in Table 1 below. Table 1: Amiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment Pharmacodynamic Interactions QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes. Avoid concomitant use. Negative Chronotropes digoxin, beta blockers, verapamil, diltiazem, clonidine, ivabradine Potentiates the electrophysiologic and hemodynamic effects of amiodarone, resulting in bradycardia, sinus arrest, and AV block. Monitor heart rate. Pharmacokinetic Interactions CYP450 Inhibitors grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors Increased exposure of amiodarone. Avoid concomitant use. CYP450 Inducers St. John's Wort Reduced amiodarone serum levels. Cyclosporine Increased plasma levels of cyclosporine have been reported resulting in elevated creatinine, despite reduction of cyclosporine dose. Monitor cyclosporine drug levels and renal function with concomitant use. Cholestyramine Reduced amiodarone serum levels. Antiarrhythmics quinidine, procainamide, flecainide Reserve concomitant use for patients who are unresponsive to a single agent. Antiarrhythmic metabolism inhibited by amiodarone. Initiate antiarrhythmic at a lower than usual dose and monitor patient carefully. Reduce dose levels of previously administered antiarrhythmic by 30% to 50% for several days after transitioning to oral amiodarone. Evaluate continued need for antiarrhythmic. Digoxin Increased digoxin concentration. Reduce digoxin by half or discontinue. If continued, monitor for evidence of toxicity. HMG-CoA Reductase Inhibitors simvastatin, lovastatin, atorvastatin Increased plasma concentration of HMG-CoA reductase inhibitor. Limit the dose of lovastatin to 40 mg. Limit the coadministered dose of simvastatin to 20 mg. Lower starting dose of other CYP3A4 substrates may be required. Warfarin Potentiates anticoagulant response and can result in serious or fatal bleeding. Coadministration increases prothrombin time by 100% after 3 to 4 days. Reduce warfarin dose by one-third to one-half and monitor prothrombin times. Phenytoin Increased steady-state levels of phenytoin. Monitor phenytoin levels. Hepatitis C Direct Acting Antiviral sofosbuvir Cases of symptomatic bradyarrhythmia requiring pacemaker insertion have been reported in patients on oral maintenance amiodarone who initiated therapy with sofosbuvir. CYP3A Substrate lidocaine Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine given for local anesthesia. Monitor heart rate. A lower starting dose of lidocaine may be required. CYP3A Substrate fentanyl Fentanyl in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output. Avoid coadministration of amiodarone with other antiarrhythmics and drugs known to prolong the QT interval. ( 7 ) Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure. ( 7 ) Amiodarone inhibits P-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs. ( 7 )"],"spl_medguide_table":["<table width=\"100%\"><col width=\"15%\" align=\"left\" valign=\"top\"/><col width=\"35%\" align=\"left\" valign=\"top\"/><col width=\"50%\" align=\"left\" valign=\"top\"/><thead><tr><th align=\"center\" styleCode=\"Lrule Rrule\" colspan=\"3\">MEDICATION GUIDE Pacerone<sup>&#xAE;</sup> (P&#x100;S-&#x259;r-&#x14D;n) Tablets (Amiodarone Hydrochloride)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\" ID=\"important\">What is the most important information I should know about Pacerone tablets?</content> <content styleCode=\"bold\">Pacerone tablets can cause serious side effects that can lead to death, including:</content><list listType=\"unordered\" styleCode=\"disc\"><item>lung problems</item><item>liver problems</item><item>worsening of heartbeat problems</item></list><content styleCode=\"bold\">Call your healthcare provider or get medical help right away if you have any of the following symptoms during treatment with Pacerone tablets:</content><list listType=\"unordered\" styleCode=\"disc\"><item>trouble breathing, wheezing, shortness of breath, coughing chest pain, spitting up of blood, or fever</item><item>nausea or vomiting, brown or dark-colored urine, feel more tired than usual, yellowing of your skin or the whites of your eyes (jaundice), or right upper stomach-area pain</item><item>heart pounding, skipping a beat, beating fast or slowly, feel light-headed, or if you faint</item><item>vision problems, including blurred vision, see halos, or your eyes become sensitive to light. You should have regular eye exams before and during treatment with Pacerone tablets.</item></list>Pacerone tablets should be started in a hospital so that your medical condition can be carefully monitored. Pacerone tablets should only be used to treat people who have been diagnosed with life-threatening heartbeat problems called ventricular arrhythmias, when other treatments did not work or you cannot tolerate them. <content styleCode=\"bold\">Pacerone tablets can cause other serious side effects. See &quot;<linkHtml href=\"#effects\">What are the possible side effects of Pacerone tablets?</linkHtml>&quot;  If you get serious side effects during treatment you may need to stop Pacerone tablets, have your dose changed, or get medical treatment. Talk with your healthcare provider before you stop taking Pacerone tablets.</content> You may still have side effects after stopping Pacerone tablets because the medicine stays in your body for months after treatment is stopped. You should have regular check-ups, blood tests, chest x-rays before and during treatment with Pacerone tablets to check for serious side effects. You should also have lung function tests before starting treatment with Pacerone tablets.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">What are Pacerone tablets?</content> Pacerone tablets are a prescription medicine used to treat people who have been diagnosed with life-threatening heartbeat problems called ventricular arrhythmias, when other treatments did not work or you cannot tolerate them. It is not known if Pacerone tablets are safe and effective in children.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Who should not take Pacerone tablets? Do not take Pacerone tablets if you:</content><list listType=\"unordered\" styleCode=\"disc\"><item>have a serious heart problem called cardiogenic shock</item><item>have certain types of the heart condition called heart block, with or without a slow heart rate</item><item>have a slow heart rate with dizziness or lightheadedness, and you do not have an implanted pacemaker</item><item>are allergic to amiodarone, iodine, or any of the other ingredients in Pacerone tablets. See the end of this Medication Guide for a complete list of ingredients in Pacerone tablets.</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Before taking Pacerone tablets, tell your healthcare provider about all of your medical conditions, including if you:</content><list listType=\"unordered\" styleCode=\"disc\"><item>have lung or breathing problems</item><item>have liver problems</item><item>have or had thyroid problems</item><item>have a slow heart rate or blood pressure problems</item><item>have diarrhea or have had diarrhea for a long period of time</item><item>have been told that you have low levels of potassium, magnesium, or calcium in your blood</item><item>have an implanted pacemaker or defibrillator</item><item>if you plan to have surgery with general anesthesia</item><item>are pregnant or plan to become pregnant. Pacerone tablets may harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with Pacerone tablets. Pacerone can stay in your body for months after treatment is stopped.</item><item>are breastfeeding or plan to breastfeed. Pacerone can pass into your breast milk and may harm your baby. You should not breast feed while taking Pacerone tablets. Pacerone can stay in your body for months after treatment is stopped. Talk to your healthcare provider about the best way to feed your baby during this time.</item></list>Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Pacerone tablets and certain other medicines can affect with each other and cause serious side effects. You can ask your pharmacist for a list of medicines that interact with Pacerone tablets.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">How should I take Pacerone tablets?</content><list listType=\"unordered\" styleCode=\"disc\"><item>When you are discharged from the hospital, take Pacerone tablets <content styleCode=\"bold\">exactly</content> as your doctor tells you to take it.</item><item>Your healthcare provider will tell you how much Pacerone to take and when to take it.</item><item>Your healthcare provider may change your dose of Pacerone as needed if your heart rhythm is controlled, or if you have certain side effects. Your healthcare provider should monitor you carefully when your dose of Pacerone is being changed.</item><item><content styleCode=\"bold\">Take your dose of Pacerone tablets the same way each time, either with or without food.</content></item><item>If you take too much Pacerone, call your healthcare provider or go to the nearest hospital emergency room right away. If you miss a dose, wait and take your next dose at your regular time. Do not take two doses at the same time. Continue with your next regularly scheduled dose.</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">What should I avoid while taking Pacerone tablets?</content><list listType=\"unordered\" styleCode=\"disc\"><item>Avoid drinking grapefruit juice during treatment with Pacerone. Drinking grapefruit juice with Pacerone tablets may increase the amount of Pacerone in your blood, and this may lead to side effects.</item><item>Pacerone tablets can make your skin sensitive to sunlight. You could get severe sunburn. Use sunscreen and wear a hat and clothes that cover your skin to help protect you if you must be in sunlight. Talk to your healthcare if you get a sunburn. See &quot;<linkHtml href=\"#SP\">Skin problems</linkHtml>&quot; in the Medication Guide section <content styleCode=\"bold\">&quot;What are the possible side effects of Pacerone tablets?&quot;</content> below.</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\" ID=\"effects\">What are the possible side effects of Pacerone tablets? Pacerone tablets can cause serious side effects, including:</content><list listType=\"unordered\" styleCode=\"disc\"><item>See <content styleCode=\"bold\">&quot;<linkHtml href=\"#important\">What is the most important information I should know about Pacerone tablets?</linkHtml>&quot;</content></item><item><content styleCode=\"bold\">Nerve problems</content>. Pacerone tablets can cause nerve problems. Call your healthcare provider if you develop symptoms of nerve problems, including: a feeling of &quot;pins and needles&quot; or numbness in your hands, legs, or feet, muscle weakness, uncontrolled movements, poor coordination, or trouble walking.</item><item><content styleCode=\"bold\" ID=\"SP\">Skin problems</content>. Pacerone tablets can cause your skin to be more sensitive to the sun or turn a bluish-gray color. People who have fair skin or people who have a lot of sun exposure may be more at risk for these skin problems. Some of the bluish-gray skin color may return to normal after stopping Pacerone tablets.</item><item><content styleCode=\"bold\">Thyroid problems.</content> Pacerone tablets can cause you to have either decreased thyroid function (hypothyroidism), which can sometimes be severe, or an overactive thyroid (hyperthyroidism), which can be severe.<list listType=\"unordered\" styleCode=\"circle\"><item>If you develop decreased thyroid function during treatment with Pacerone tablets, your healthcare provider may need to reduce your dose or stop your treatment with Pacerone tablets, and possibly prescribe medicine to replace your thyroid hormone.</item><item>An overactive thyroid can cause you to produce too much thyroid hormone. You can have abnormal heartbeats even while you are receiving Pacerone tablets. Your healthcare provider may prescribe certain medicines to treat your overactive thyroid. Call your healthcare provider if you get any abnormal heartbeats during treatment with Pacerone tablets. This may mean that you have an overactive thyroid.</item><item>Your healthcare provider should do tests to check your thyroid function before you start and during treatment with Pacerone tablets.</item><item>Call your healthcare provider if you develop any of the following symptoms of a thyroid problem during treatment with Pacerone tablets:</item></list></item></list></td></tr><tr><td styleCode=\"Lrule\"/><td><list listType=\"unordered\" styleCode=\"square\"><item>weakness</item><item>weight loss or weight gain</item><item>heat or cold intolerance</item><item>hair thinning</item><item>sweating</item><item>changes in your menstrual periods</item><item>swelling of your neck (goiter)</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"Square\"><item>nervousness</item><item>irritability</item><item>restlessness</item><item>decreased concentration</item><item>feeling depressed (in the elderly)</item><item>tremor</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\">The most common side effects of Pacerone tablets include:<list listType=\"unordered\" styleCode=\"disc\"><item>lung problems</item><item>heartbeat problems</item><item>heart problems</item><item>liver problems</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\">Pacerone tablets may affect fertility in males and females. It is not known if the effects are reversible. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of Pacerone tablets. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">How should I store Pacerone tablets?</content><list listType=\"unordered\" styleCode=\"disc\"><item>Store Pacerone tablets at room temperature between 20&#xB0; to 25&#xB0;C (68&#xB0; to 77&#xB0;F).</item><item>Keep Pacerone tablets in a tightly closed container and keep Pacerone tablets out of the light.</item><item>Pacerone comes in a child-resistant package.</item></list><content styleCode=\"bold\">Keep Pacerone tablets and all medicines out of the reach of children.</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">General information about the safe and effective use of Pacerone tablets</content> Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Pacerone tablets for a condition for which it was not prescribed. Do not give Pacerone tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Pacerone tablets that is written for health professionals.</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">What are the ingredients in Pacerone tablets?</content> <content styleCode=\"bold\">Active Ingredient</content>: amiodarone hydrochloride <content styleCode=\"bold\">Inactive Ingredients</content>: lactose monohydrate, magnesium stearate, povidone, pregelatinized corn starch, sodium starch glycolate, stearic acid, FD&amp;C Red No. 40 (200 mg) and FD&amp;C Yellow No. 6 (100 mg and 200 mg). For more information and the most current Medication Guide, please visit www.upsher-smith.com or call 1-888-650-3789.</td></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. One of its main effects, with prolonged administration, is to lengthen the cardiac action potential, a class III effect. The negative chronotropic effect of amiodarone in nodal tissues is similar to the effect of class IV drugs. In addition to blocking sodium channels, amiodarone blocks myocardial potassium channels, which contributes to slowing of conduction and prolongation of refractoriness. The antisympathetic action and the block of calcium and potassium channels are responsible for the negative dromotropic effects on the sinus node and for the slowing of conduction and prolongation of refractoriness in the atrioventricular (AV) node. Its vasodilatory action can decrease cardiac workload and consequently myocardial oxygen consumption. Pacerone prolongs the duration of the action potential of all cardiac fibers while causing minimal reduction of dV/dt (maximal upstroke velocity of the action potential). The refractory period is prolonged in all cardiac tissues. Amiodarone hydrochloride increases the cardiac refractory period without influencing resting membrane potential, except in automatic cells where the slope of the prepotential is reduced, generally reducing automaticity. These electrophysiologic effects are reflected in a decreased sinus rate of 15% to 20%, increased PR and QT intervals of about 10%, the development of U-waves, and changes in T-wave contour. These changes should not require discontinuation of Pacerone as they are evidence of its pharmacological action, although Pacerone can cause marked sinus bradycardia or sinus arrest and heart block [see Warnings and Precautions (5.4) ] . Hemodynamics In animal studies and after intravenous administration in man, amiodarone hydrochloride relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. After oral dosing, however, amiodarone hydrochloride produces no significant change in left ventricular ejection fraction (LVEF), even in patients with depressed LVEF. After acute intravenous dosing in man, amiodarone hydrochloride may have a mild negative inotropic effect."],"storage_and_handling":["Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container with a child-resistant closure."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. One of its main effects, with prolonged administration, is to lengthen the cardiac action potential, a class III effect. The negative chronotropic effect of amiodarone in nodal tissues is similar to the effect of class IV drugs. In addition to blocking sodium channels, amiodarone blocks myocardial potassium channels, which contributes to slowing of conduction and prolongation of refractoriness. The antisympathetic action and the block of calcium and potassium channels are responsible for the negative dromotropic effects on the sinus node and for the slowing of conduction and prolongation of refractoriness in the atrioventricular (AV) node. Its vasodilatory action can decrease cardiac workload and consequently myocardial oxygen consumption. Pacerone prolongs the duration of the action potential of all cardiac fibers while causing minimal reduction of dV/dt (maximal upstroke velocity of the action potential). The refractory period is prolonged in all cardiac tissues. Amiodarone hydrochloride increases the cardiac refractory period without influencing resting membrane potential, except in automatic cells where the slope of the prepotential is reduced, generally reducing automaticity. These electrophysiologic effects are reflected in a decreased sinus rate of 15% to 20%, increased PR and QT intervals of about 10%, the development of U-waves, and changes in T-wave contour. These changes should not require discontinuation of Pacerone as they are evidence of its pharmacological action, although Pacerone can cause marked sinus bradycardia or sinus arrest and heart block [see Warnings and Precautions (5.4) ] . Hemodynamics In animal studies and after intravenous administration in man, amiodarone hydrochloride relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. After oral dosing, however, amiodarone hydrochloride produces no significant change in left ventricular ejection fraction (LVEF), even in patients with depressed LVEF. After acute intravenous dosing in man, amiodarone hydrochloride may have a mild negative inotropic effect. 12.2 Pharmacodynamics There is no well-established relationship between plasma concentration and effectiveness, but it does appear that concentrations much below 1 mg/L are often ineffective and that levels above 2.5 mg/L are generally not needed. Plasma-concentration measurements can be used to identify patients whose levels are unusually low, and who might benefit from a dose increase, or unusually high, and who might have dosage reduction in the hope of minimizing side effects. Effects on abnormal rhythms are not seen before 2 to 3 days and usually require 1 to 3 weeks, even when a loading dose is used. There may be a continued increase in effect for longer periods still. There is evidence that the time to effect is shorter when a loading-dose regimen is used. Consistent with the slow rate of elimination, antiarrhythmic effects persist for weeks or months after amiodarone hydrochloride is discontinued, but the time of recurrence is variable and unpredictable. In general, when the drug is resumed after recurrence of the arrhythmia, control is established relatively rapidly compared to the initial response, presumably because tissue stores were not wholly depleted. 12.3 Pharmacokinetics Absorption Following oral administration in humans, amiodarone hydrochloride is slowly and variably absorbed. The bioavailability of amiodarone hydrochloride is approximately 50%. Maximum plasma concentrations are attained 3 to 7 hours after a single dose. Plasma concentrations with chronic dosing at 100 to 600 mg/day are approximately dose proportional, with a mean 0.5 mg/L increase for each 100 mg/day. These means, however, include considerable individual variability. Food increases the rate and extent of absorption of amiodarone hydrochloride. The effects of food upon the bioavailability of amiodarone hydrochloride have been studied in 30 healthy subjects who received a single 600-mg dose immediately after consuming a high-fat meal and following an overnight fast. The area under the plasma concentration-time curve (AUC) and the peak plasma concentration (C max ) of amiodarone increased by 2.3 (range 1.7 to 3.6) and 3.8 (range 2.7 to 4.4) times, respectively, in the presence of food. Food also increased the rate of absorption of amiodarone, decreasing the time to peak plasma concentration (T max ) by 37%. The mean AUC and mean C max of the major metabolite of amiodarone, DEA increased by 55% (range 58% to 101%) and 32% (range 4% to 84%), respectively, but there was no change in the T max in the presence of food. Distribution Pacerone is highly protein-bound (approximately 96%). Pacerone has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen. One major metabolite of amiodarone hydrochloride, DEA, has been identified in man; it accumulates to an even greater extent in almost all tissues. No data are available on the activity of DEA in humans, but in animals, it has significant electrophysiologic and antiarrhythmic effects generally similar to amiodarone itself. DEA's precise role and contribution to the antiarrhythmic activity of oral amiodarone are not certain. The development of maximal ventricular class III effects after oral amiodarone hydrochloride administration in humans correlates more closely with DEA accumulation over time than with amiodarone accumulation. Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA). In patients, following discontinuation of chronic oral therapy, amiodarone hydrochloride has been shown to have a biphasic elimination with an initial 50% reduction of plasma levels after 2.5 to 10 days. A much slower terminal plasma-elimination phase shows a half-life of the parent compound ranging from 26 to 107 days, with a mean of approximately 53 days and most patients in the 40- to 55-day range. In the absence of a loading-dose period, steady-state plasma concentrations, at constant oral dosing, would therefore be reached between 130 and 535 days, with an average of 265 days. For the metabolite, the mean plasma-elimination half-life was approximately 61 days. These data probably reflect an initial elimination of drug from well-perfused tissue (the 2.5- to 10-day half-life phase), followed by a terminal phase representing extremely slow elimination from poorly perfused tissue compartments such as fat. The considerable inter-subject variation in both phases of elimination, as well as uncertainty as to what compartment is critical to drug effect, requires attention to individual responses once arrhythmia control is achieved with loading doses because the correct maintenance dose is determined, in part, by the elimination rates. Individualize maintenance doses of Pacerone tablets [see Dosage and Administration (2) ] . Metabolism Amiodarone is metabolized to DEA by the cytochrome P450 (CYP) enzyme group, specifically CYP3A and CYP2C8. The CYP3A isoenzyme is present in both the liver and intestines. In vitro , amiodarone and DEA exhibit a potential to inhibit CYP2C9, CYP2C19, CYP2D6, CYP3A, CYP2A6, CYP2B6 and CYP2C8. Amiodarone and DEA have also a potential to inhibit some transporters such as P-glycoprotein and organic cation transporter (OCT2). Excretion Amiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine. Neither amiodarone nor DEA is dialyzable. Specific Populations Effect of Age: Normal subjects over 65 years of age show lower clearances (about 100 mL/hr/kg) than younger subjects (about 150 mL/hr/kg) and an increase in t½ from about 20 to 47 days. Renal Impairment: Renal impairment does not influence the pharmacokinetics of amiodarone or DEA. Hepatic Impairment: After a single dose of intravenous amiodarone to cirrhotic patients, significantly lower C max and average concentration values are seen for DEA, but mean amiodarone levels are unchanged. Cardiac Disease: In patients with severe left ventricular dysfunction, the pharmacokinetics of amiodarone are not significantly altered but the terminal elimination t½ of DEA is prolonged. Although no dosage adjustment for patients with renal, hepatic, or cardiac abnormalities has been defined during chronic treatment with oral amiodarone, close clinical monitoring is prudent for elderly patients and those with severe left ventricular dysfunction. Drug Interactions: Effects of other agents on amiodarone Grapefruit juice: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and C max by 84%, and decreased DEA to unquantifiable concentrations. Cimetidine inhibits CYP3A and can increase serum amiodarone levels. Cholestyramine reduces enterohepatic circulation of amiodarone thereby increasing its elimination. This results in reduced amiodarone serum levels and half-life. Effects of amiodarone on agents CYP3A substrates: Amiodarone taken concomitantly with quinidine increases the quinidine serum concentration by 33% after two days. Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively. Loratadine , a non-sedating antihistaminic, is metabolized primarily by CYP3A and its metabolism can be inhibited by amiodarone. Metabolism of lidocaine can be inhibited by amiodarone. Cyclophosphamide is a prodrug, metabolized by CYP450 including CYP3A to an active metabolite. The metabolism of cyclophosphamide may be inhibited by amiodarone. Clopidogrel , an inactive thienopyridine prodrug, is metabolized in the liver by CYP3A to an active metabolite. A potential interaction between clopidogrel and amiodarone resulting in ineffective inhibition of platelet aggregation has been reported. Macrolide/ketolide antibiotics: Amiodarone can inhibit the metabolism of macrolide/ketolide antibiotics (except for azithromycin) and systemic azole antifungal drugs. P-glycoprotein substrates: Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day. Dabigatran etexilate when taken concomitantly with oral amiodarone can result in elevated serum concentration of dabigatran. Dextromethorphan is a substrate for both CYP2D6 and CYP3A. Amiodarone inhibits CYP2D6. Chronic (>2 weeks) oral amiodarone administration impairs metabolism of dextromethorphan can lead to increased serum concentrations."],"indications_and_usage":["1 INDICATIONS AND USAGE Pacerone is indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. Pacerone is an antiarrhythmic indicated for: Recurrent ventricular fibrillation. ( 1 ) Recurrent hemodynamically unstable ventricular tachycardia. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Persistence of Adverse Effects: Adverse reactions and drug interaction can persist for several weeks following discontinuation. ( 5.1 ) Impaired Vision: Corneal microdeposits (common; reversible), optic neuropathy/neuritis (rare; may lead to blindness). ( 5.5 ) Thyroid Abnormalities: Hyperthyroidism or hypothyroidism. ( 5.6 ) 5.1 Persistence of Adverse Effects Because of the long half-life of amiodarone (15 to 142 days) and its active metabolite desethylamiodarone (14 to 75 days), adverse reactions and drug interactions can persist for several weeks following amiodarone discontinuation [see Clinical Pharmacology (12.3) ] . 5.2 Pulmonary Toxicity Pacerone may cause a clinical syndrome of cough and progressive dyspnea accompanied by functional, radiographic, gallium-scan, and pathological data consistent with pulmonary toxicity. Pulmonary toxicity secondary to Pacerone may result from either indirect or direct toxicity as represented by hypersensitivity pneumonitis (including eosinophilic pneumonia) or interstitial/alveolar pneumonitis, respectively. Rates of pulmonary toxicity have been reported to be as high as 17% and is fatal in about 10% of cases. Obtain a baseline chest X-ray and pulmonary-function tests, including diffusion capacity, when Pacerone therapy is initiated. Repeat history, physical exam, and chest X-ray every 3 to 6 months or if symptoms occur. Consider alternative antiarrhythmic therapy if the patient experiences signs or symptoms of pulmonary toxicity. Prednisone 40 to 60 mg/day tapered over several weeks may be helpful in treating pulmonary toxicity. Adult Respiratory Distress Syndrome (ARDS) Postoperatively, occurrences of ARDS have been reported in patients receiving amiodarone hydrochloride therapy who have undergone either cardiac or noncardiac surgery. Although patients usually respond well to vigorous respiratory therapy, in rare instances the outcome has been fatal. 5.3 Hepatic Injury Asymptomatic elevations of hepatic enzyme levels are seen frequently, but Pacerone can cause life-threatening hepatic injury. Histology has resembled that of alcoholic hepatitis or cirrhosis. Obtain baseline and periodic liver transaminases. If transaminases exceed three times normal, or doubles in a patient with an elevated baseline, discontinue or reduce dose of Pacerone, obtain follow-up tests and treat appropriately. 5.4 Worsened Arrhythmia Pacerone can exacerbate the presenting arrhythmia in about 2% to 5% of patients or cause new ventricular fibrillation, incessant ventricular tachycardia, increased resistance to cardioversion, and polymorphic ventricular tachycardia associated with QTc prolongation (Torsade de Pointes [TdP]). Correct hypokalemia, hypomagnesemia, and hypocalcemia before initiating treatment with amiodarone hydrochloride, as these disorders can exaggerate the degree of QTc prolongation and increase the potential for TdP. Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or receiving drugs affecting electrolyte levels, such as diuretics, laxatives, systemic corticosteroids, or amphotericin B. 5.5 Visual Impairment and Loss of Vision Optic Neuropathy and Optic Neuritis Cases of optic neuropathy and optic neuritis, usually resulting in visual impairment and sometimes permanent blindness, have been reported in patients treated with amiodarone and may occur at any time during therapy. If symptoms of visual impairment appear, such as changes in visual acuity and decreases in peripheral vision, consider discontinuing Pacerone and promptly refer for ophthalmic examination. Regular ophthalmic examination, including funduscopy and slit-lamp examination, is recommended during administration of Pacerone [see Adverse Reactions (6.1) ] . Corneal Microdeposits Corneal microdeposits appear in the majority of adults treated with amiodarone hydrochloride. They are usually discernible only by slit-lamp examination but give rise to symptoms such as visual halos or blurred vision in as many as 10% of patients. Corneal microdeposits are reversible upon reduction of dose or termination of treatment. Asymptomatic microdeposits alone are not a reason to reduce dose or discontinue treatment [see Adverse Reactions (6.1) ] . 5.6 Thyroid Abnormalities Amiodarone hydrochloride inhibits peripheral conversion of thyroxine (T 4 ) to triiodothyronine (T 3 ) and may cause increased thyroxine levels, decreased T 3 levels, and increased levels of inactive reverse T 3 (rT 3 ) in clinically euthyroid patients. Amiodarone hydrochloride can cause either hypothyroidism (reported in up to 10% of patients) or hyperthyroidism (occurring in about 2% of patients). Monitor thyroid function prior to treatment and periodically thereafter, particularly in elderly patients, and in any patient with a history of thyroid nodules, goiter, or other thyroid dysfunction. Hyperthyroidism may induce arrhythmia breakthrough. If any new signs of arrhythmia appear, the possibility of hyperthyroidism should be considered. Antithyroid drugs, β-adrenergic blockers, temporary corticosteroid therapy may be necessary to treat the symptoms of hyperthyroidism. The action of antithyroid drugs may be delayed in amiodarone-induced thyrotoxicosis because of substantial quantities of preformed thyroid hormones stored in the gland. Radioactive iodine therapy is contraindicated because of the low radioiodine uptake associated with amiodarone-induced hyperthyroidism. Pacerone-induced hyperthyroidism may be followed by a transient period of hypothyroidism. Hypothyroidism may be primary or subsequent to resolution of preceding amiodarone-induced hyperthyroidism. Severe hypothyroidism and myxedema coma, sometimes fatal, have been reported in association with amiodarone therapy. In some clinically hypothyroid amiodarone-treated patients, free thyroxine index values may be normal. Manage hypothyroidism by reducing the dose of or discontinuing Pacerone and thyroid hormone supplementation. 5.7 Bradycardia Pacerone causes symptomatic bradycardia or sinus arrest with suppression of escape foci in 2% to 4% of patients. The risk is increased by electrolytic disorders or use of concomitant antiarrhythmics or negative chronotropes [see Drug Interactions (7) ] . Bradycardia may require a pacemaker for rate control. Post-marketing cases of symptomatic bradycardia, some requiring pacemaker insertion and at least one fatal, have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone. Bradycardia generally occurred within hours to days, but in some cases presented up to 2 weeks after initiating antiviral treatment. Bradycardia generally resolved after discontinuation of antiviral treatment. The mechanism for this effect is unknown. Monitor heart rate in patients taking or recently discontinuing amiodarone when starting antiviral treatment [see Drug Interactions (7) ] . 5.8 Implantable Cardiac Devices In patients with implanted defibrillators or pacemakers, chronic administration of antiarrhythmic drugs may affect pacing or defibrillation thresholds. Therefore, at the inception of and during amiodarone treatment, pacing and defibrillation thresholds should be assessed. 5.9 Fetal Toxicity Pacerone may cause fetal harm when administered to a pregnant woman. Fetal exposure may increase the potential for cardiac, thyroid, neurodevelopmental, neurological, and growth effects in neonate [see Use in Specific Populations (8.1) ] . 5.10 Peripheral Neuropathy Chronic administration of Pacerone may lead to peripheral neuropathy, which may not resolve when Pacerone is discontinued. 5.11 Photosensitivity and Skin Discoloration Pacerone induces photosensitization in about 10% of patients; some protection may be afforded sun-barrier creams or protective clothing. During long-term treatment, a blue-gray discoloration of the exposed skin may occur. The risk may be increased in patients of fair complexion or those with excessive sun exposure. Some reversal of discoloration may occur upon drug discontinuation. 5.12 Surgery Volatile Anesthetic Agents Patients on Pacerone therapy may be more sensitive to the myocardial depressant and conduction effects of halogenated inhalational anesthetics."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Amiodarone hydrochloride was associated with a statistically significant, dose-related increase in the incidence of thyroid tumors (follicular adenoma and/or carcinoma) in rats. The incidence of thyroid tumors was greater than control at the lowest dose level tested, i.e., 5 mg/kg/day (approximately 0.08 times the maximum recommended human maintenance dose 600 mg in a 60 kg patient (dose compared on a body surface area basis) ). Mutagenicity studies (Ames, micronucleus, and lysogenic tests) with amiodarone hydrochloride were negative. In a study in which amiodarone hydrochloride was administered to male and female rats, beginning 9 weeks prior to mating, reduced fertility was observed at a dose level of 90 mg/kg/day (approximately 1.4 times the maximum recommended human maintenance dose )."],"drug_interactions_table":["<table width=\"75%\"><caption>Table 1: Amiodarone Drug Interactions</caption><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"35%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Concomitant Drug Class/Name</th><th styleCode=\"Rrule\">Examples</th><th styleCode=\"Rrule\">Clinical Comment</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\" align=\"center\"><content styleCode=\"italics\">Pharmacodynamic Interactions</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">QT Prolonging Drugs</td><td styleCode=\"Rrule\">class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents</td><td styleCode=\"Rrule\">Increased risk of Torsade de Pointes. Avoid concomitant use.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Negative Chronotropes</td><td styleCode=\"Rrule\">digoxin, beta blockers, verapamil, diltiazem, clonidine, ivabradine</td><td styleCode=\"Rrule\">Potentiates the electrophysiologic and hemodynamic effects of amiodarone, resulting in bradycardia, sinus arrest, and AV block. Monitor heart rate.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\" align=\"center\"><content styleCode=\"italics\">Pharmacokinetic Interactions</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">CYP450 Inhibitors</td><td styleCode=\"Rrule\">grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors</td><td styleCode=\"Rrule\">Increased exposure of amiodarone. Avoid concomitant use.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">CYP450 Inducers</td><td styleCode=\"Rrule\">St. John&apos;s Wort</td><td styleCode=\"Rrule\">Reduced amiodarone serum levels.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Cyclosporine</td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\">Increased plasma levels of cyclosporine have been reported resulting in elevated creatinine, despite reduction of cyclosporine dose. Monitor cyclosporine drug levels and renal function with concomitant use.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Cholestyramine</td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\">Reduced amiodarone serum levels.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Antiarrhythmics</td><td styleCode=\"Rrule\">quinidine, procainamide, flecainide</td><td styleCode=\"Rrule\">Reserve concomitant use for patients who are unresponsive to a single agent. Antiarrhythmic metabolism inhibited by amiodarone. Initiate antiarrhythmic at a lower than usual dose and monitor patient carefully. Reduce dose levels of previously administered antiarrhythmic by 30% to 50% for several days after transitioning to oral amiodarone. Evaluate continued need for antiarrhythmic.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Digoxin</td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\">Increased digoxin concentration. Reduce digoxin by half or discontinue. If continued, monitor for evidence of toxicity.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">HMG-CoA Reductase Inhibitors</td><td styleCode=\"Rrule\">simvastatin, lovastatin, atorvastatin</td><td styleCode=\"Rrule\">Increased plasma concentration of HMG-CoA reductase inhibitor. Limit the dose of lovastatin to 40 mg. Limit the coadministered dose of simvastatin to 20 mg. Lower starting dose of other CYP3A4 substrates may be required.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Warfarin</td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\">Potentiates anticoagulant response and can result in serious or fatal bleeding. Coadministration increases prothrombin time by 100% after 3 to 4 days. Reduce warfarin dose by one-third to one-half and monitor prothrombin times.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Phenytoin</td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\">Increased steady-state levels of phenytoin. Monitor phenytoin levels.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hepatitis C Direct Acting Antiviral</td><td styleCode=\"Rrule\">sofosbuvir</td><td styleCode=\"Rrule\">Cases of symptomatic bradyarrhythmia requiring pacemaker insertion have been reported in patients on oral maintenance amiodarone who initiated therapy with sofosbuvir.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">CYP3A Substrate</td><td styleCode=\"Rrule\">lidocaine</td><td styleCode=\"Rrule\">Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine given for local anesthesia. Monitor heart rate. A lower starting dose of lidocaine may be required.</td></tr><tr><td styleCode=\"Lrule Rrule\">CYP3A Substrate</td><td styleCode=\"Rrule\">fentanyl</td><td styleCode=\"Rrule\">Fentanyl in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy [see Use in Specific Populations (8.1) ] . Advise women that breastfeeding is not recommended during treatment with Pacerone [see Use in Specific Populations (8.2) ] . Advise patients to avoid grapefruit juice and St. John's Wort. Advise patients to seek medical attention if they experience the signs and symptoms of pulmonary toxicity, worsening arrhythmia, bradycardia, visual impairment, or hypo- and hyperthyroidism. This product's label may have been updated. For full prescribing information, please visit www.upsher-smith.com."],"spl_unclassified_section":["Manufactured by UPSHER-SMITH LABORATORIES, LLC Maple Grove, MN 55369 Pacerone is a registered trademark of Upsher-Smith Laboratories, LLC. Revised: 9/2020","Repackaging Information Please reference the How Supplied section listed above for a description of individual tablets. This drug product has been received by Aphena Pharma - TN in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations. The package configurations available from Aphena are listed below: Count 200 mg 30 71610-787-30 Store between 20°-25°C (68°-77°F). See USP Controlled Room Temperature. Dispense in a tight light-resistant container as defined by USP. Keep this and all drugs out of the reach of children. Repackaged by: Cookeville, TN 38506 20240202JK Aphena Pharma Solutions - TN"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Dosage must be individualized based on severity of arrhythmia and response. Use the lowest effective dose. Obtain baseline chest x-ray, pulmonary function tests, thyroid function tests, and liver aminotransferases. Correct hypokalemia, hypomagnesemia, and hypocalcemia before initiating treatment. Initiate treatment with a loading dose of 800 to 1600 mg/day until initial therapeutic response occurs (usually 1 to 3 weeks). Once adequate arrhythmia control is achieved, or if side effects become prominent, reduce Pacerone tablets dose to 600 to 800 mg/day for one month and then to the maintenance dose, usually 400 mg/day. ( 2 ) Recommended Dosage: Initiate treatment with a loading dose of 800 to 1600 mg/day until initial therapeutic response occurs (usually 1 to 3 weeks). Once adequate arrhythmia control is achieved, or if side effects become prominent, reduce Pacerone tablet dose to 600 to 800 mg/day for one month and then to the maintenance dose, usually 400 mg/day. Administration: Administer Pacerone tablets consistently with regard to meals [see Clinical Pharmacology (12.3) ] . Administration of Pacerone tablets in divided doses with meals is suggested for total daily doses of 1000 mg or higher, or when gastrointestinal intolerance occurs."],"spl_product_data_elements":["Pacerone Amiodarone Hydrochloride Amiodarone Hydrochloride Amiodarone lactose monohydrate magnesium stearate povidone, unspecified starch, corn sodium starch glycolate type A potato stearic acid FD&C Yellow No. 6 FD&C Red No. 40 P200;U;S;0147"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Pacerone tablets, 100 mg, are peach, round, flat-faced, uncoated tablets, debossed with \"P\" on one side, and \"U-S\" above \"144\" on the other side. Pacerone tablets, 200 mg, are pink, round, flat-faced, scored, uncoated tablets, debossed with \"P 200 \" on the unscored side, and \"U-S\" above and \"0147\" below the score on the reverse side. Pacerone tablets, 400 mg, are white to off-white, round, uncoated, scored tablets, debossed with \"U-S' above and \"1645' below the score on one side and \"P 400 \" on the unscored side. Tablets: 100 mg, 200 mg and 400 mg ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. ( 8.1 ) Lactation: Breastfeeding not recommended. ( 8.2 ) 8.1 Pregnancy Risk Summary Available data from post-marketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. Amiodarone and its metabolite, desethylamiodarone (DEA), cross the placenta. Untreated underlying arrhythmias, including ventricular arrhythmias, during pregnancy pose a risk to the mother and fetus (see Clinical Considerations ) . In animal studies, administration of amiodarone to rabbits, rats, and mice during organogenesis resulted in embryo-fetal toxicity at doses less than the maximum recommended human maintenance dose (see Data ) . Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk The incidence of ventricular tachycardia is increased and may be more symptomatic during pregnancy. Ventricular arrhythmias most often occur in pregnant women with underlying cardiomyopathy, congenital heart disease, valvular heart disease, or mitral valve prolapse. Most tachycardia episodes are initiated by ectopic beats and the occurrence of arrhythmia episodes may, therefore, increase during pregnancy due to the increased propensity to ectopic activity. Breakthrough arrhythmias may also occur during pregnancy, as therapeutic treatment levels may be difficult to maintain due to the increased volume of distribution and increased drug metabolism inherent in the pregnant state. Fetal/Neonatal adverse reactions Amiodarone and its metabolite have been shown to cross the placenta. Adverse fetal effects associated with maternal amiodarone use during pregnancy may include neonatal bradycardia, QT prolongation, and periodic ventricular extrasystoles, neonatal hypothyroidism (with or without goiter) detected antenatally or in the newborn and reported even after a few days of exposure, neonatal hyperthyroxinemia, neurodevelopmental abnormalities independent of thyroid function, including speech delay and difficulties with written language and arithmetic, delayed motor development, and ataxia, jerk nystagmus with synchronous head titubation, fetal growth restriction, and premature birth. Monitor the newborn for signs and symptoms of thyroid disorder and cardiac arrhythmias. Labor and Delivery Risk of arrhythmias may increase during labor and delivery. Patients treated with Pacerone should be monitored continuously during labor and delivery [see Warnings and Precautions (5.4) ] . Data Animal Data In pregnant rats and rabbits during the period of organogenesis, amiodarone hydrochloride in doses of 25 mg/kg/day (approximately 0.4 and 0.9 times, respectively, the maximum recommended human maintenance dose 600 mg in a 60 kg patient (doses compared on a body surface area basis) ) had no adverse effects on the fetus. In the rabbit, 75 mg/kg/day (approximately 2.7 times the maximum recommended human maintenance dose ) caused abortions in greater than 90% of the animals. In the rat, doses of 50 mg/kg/day or more were associated with slight displacement of the testes and an increased incidence of incomplete ossification of some skull and digital bones; at 100 mg/kg/day or more, fetal body weights were reduced; at 200 mg/kg/day, there was an increased incidence of fetal resorption. (These doses in the rat are approximately 0.8, 1.6 and 3.2 times the maximum recommended human maintenance dose ) Adverse effects on fetal growth and survival also were noted in one of two strains of mice at a dose of 5 mg/kg/day (approximately 0.04 times the maximum recommended human maintenance dose ). 8.2 Lactation Risk Summary Amiodarone and one of its major metabolites, DEA, are present in breastmilk at between 3.5% and 45% of the maternal weight-adjusted dosage of amiodarone. There are cases of hypothyroidism and bradycardia in breastfed infants, although it is unclear if these effects are due to amiodarone exposure in breastmilk. Breastfeeding is not recommended during treatment with Pacerone [see Warnings and Precautions (5.6 , 5.7) ] . 8.3 Females and Males of Reproductive Potential Infertility Based on animal fertility studies, amiodarone hydrochloride may reduce female and male fertility. It is not known if this effect is reversible [see Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use The safety and effectiveness of Pacerone in pediatric patients have not been established. 8.5 Geriatric Use Normal subjects over 65 years of age show lower clearances and increased drug half-life than younger subjects [see Clinical Pharmacology (12.3) ] . In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"spl_unclassified_section_table":["<table border=\"0\" cellpadding=\"1\" cellspacing=\"1\" width=\"28%\"><colgroup><col width=\"10%\"/><col/></colgroup><tbody><tr styleCode=\"Toprule\"><td valign=\"bottom\" align=\"center\" styleCode=\"bold\">Count</td><td valign=\"bottom\" align=\"center\"><content styleCode=\"bold\">200 mg</content></td></tr><tr><td valign=\"bottom\" align=\"center\">30</td><td align=\"center\">71610-787-30</td></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 200 mg NDC 71610-787 - Amiodarone HCl (Pacerone) 200 mg Tablets - Rx Only Bottle Label 200 mg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Amiodarone hydrochloride was associated with a statistically significant, dose-related increase in the incidence of thyroid tumors (follicular adenoma and/or carcinoma) in rats. The incidence of thyroid tumors was greater than control at the lowest dose level tested, i.e., 5 mg/kg/day (approximately 0.08 times the maximum recommended human maintenance dose 600 mg in a 60 kg patient (dose compared on a body surface area basis) ). Mutagenicity studies (Ames, micronucleus, and lysogenic tests) with amiodarone hydrochloride were negative. In a study in which amiodarone hydrochloride was administered to male and female rats, beginning 9 weeks prior to mating, reduced fertility was observed at a dose level of 90 mg/kg/day (approximately 1.4 times the maximum recommended human maintenance dose )."]},"tags":[{"label":"Antiarrhythmic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase","category":"target"},{"label":"EBP","category":"gene"},{"label":"CYP2C9","category":"gene"},{"label":"SCN5A","category":"gene"},{"label":"C01BD01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Life-Threatening Ventricular Tachycardia","category":"indication"},{"label":"Prevention of Ventricular Fibrillation","category":"indication"},{"label":"Ventricular fibrillation","category":"indication"},{"label":"Wyeth Pharms Inc","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Cytochrome P-450 CYP1A2 Inhibitors","category":"pharmacology"},{"label":"Cytochrome P-450 CYP2C9 Inhibitors","category":"pharmacology"},{"label":"Cytochrome P-450 CYP2D6 Inhibitors","category":"pharmacology"},{"label":"Cytochrome P-450 CYP3A Inhibitors","category":"pharmacology"},{"label":"Cytochrome P-450 Enzyme Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Metabolic Side Effects of Drugs and Substances","category":"pharmacology"},{"label":"Potassium Channel Blockers","category":"pharmacology"},{"label":"Sodium Channel Blockers","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: PULMONARY, HEPATIC and CARDIAC TOXICITY Pacerone is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity [see Indications and Usage (1) ] . Pacerone can cause pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 17% in some series of patients. Pulmonary toxicity has been fatal about 10% of the time . Obtain a baseline chest X-ray and pulmonary-function tests, including diffusion capacity, when Pacerone therapy is initiated. Repeat history, physical exam, and chest X-ray every 3 to 6 months [see Warnings and Precautions 5.2) ] . Pacerone can cause hepatoxicity, which can be fatal. Obtain baseline and periodic liver transaminases and discontinue or reduce dose if the increase exceeds three times normal, or doubles in a patient with an elevated baseline. Discontinue Pacerone if the patient experiences signs or symptoms of clinical liver injury [see Warnings and Precautions (5.3) ] . Pacerone can exacerbate arrhythmias. Initiate amiodarone hydrochloride in a clinical setting where continuous electrocardiograms and cardiac resuscitation are available [see Warnings and Precautions (5.4) ] . WARNING: PULMONARY, HEPATIC, and CARDIAC TOXICITY See full prescribing information for complete boxed warning. Reserve Pacerone for patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity, some also life-threatening. Utilize alternative agents first. ( 1 ) Pacerone' s life-threatening toxicities include pulmonary ( 5.2 ), hepatic ( 5.3 ), and proarrhythmic ( 5.4 ). Initiate under hospital or specialist supervision. ( 5 )"],"safetySignals":[{"llr":2973.927,"date":"","count":1186,"signal":"Hyperthyroidism","source":"DrugCentral FAERS","actionTaken":"Reported 1,186 times (LLR=2974)"},{"llr":2146.617,"date":"","count":2982,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 2,982 times (LLR=2147)"},{"llr":1605.452,"date":"","count":1492,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 1,492 times (LLR=1605)"},{"llr":1270.493,"date":"","count":1111,"signal":"Electrocardiogram QT prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 1,111 times (LLR=1270)"},{"llr":1230.636,"date":"","count":602,"signal":"Torsade de pointes","source":"DrugCentral FAERS","actionTaken":"Reported 602 times (LLR=1231)"},{"llr":1206.47,"date":"","count":1598,"signal":"Atrial fibrillation","source":"DrugCentral FAERS","actionTaken":"Reported 1,598 times (LLR=1206)"},{"llr":1129.203,"date":"","count":1154,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 1,154 times (LLR=1129)"},{"llr":1110.478,"date":"","count":534,"signal":"Pulmonary toxicity","source":"DrugCentral FAERS","actionTaken":"Reported 534 times (LLR=1110)"},{"llr":1096.826,"date":"","count":1333,"signal":"Cardiac failure","source":"DrugCentral FAERS","actionTaken":"Reported 1,333 times (LLR=1097)"},{"llr":1077.385,"date":"","count":730,"signal":"Ventricular tachycardia","source":"DrugCentral FAERS","actionTaken":"Reported 730 times (LLR=1077)"},{"llr":812.527,"date":"","count":2250,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 2,250 times (LLR=813)"},{"llr":678.965,"date":"","count":545,"signal":"Cardiogenic shock","source":"DrugCentral FAERS","actionTaken":"Reported 545 times (LLR=679)"},{"llr":668.312,"date":"","count":631,"signal":"Hypothyroidism","source":"DrugCentral FAERS","actionTaken":"Reported 631 times (LLR=668)"},{"llr":653.195,"date":"","count":737,"signal":"International normalised ratio increased","source":"DrugCentral FAERS","actionTaken":"Reported 737 times (LLR=653)"},{"llr":584.396,"date":"","count":234,"signal":"Thyroiditis","source":"DrugCentral FAERS","actionTaken":"Reported 234 times (LLR=584)"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Highest Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"},{"url":"/drug/p-glycoprotein-substrates","drug":"P-glycoprotein Substrates","action":"Use caution","effect":"P-glycoprotein Inhibitors - P-glycoprotein Substrates","source":"DrugCentral","drugSlug":"p-glycoprotein-substrates"},{"url":"/drug/abarelix","drug":"abarelix","action":"Avoid combination","effect":"May interact with Abarelix","source":"DrugCentral","drugSlug":"abarelix"},{"url":"/drug/anisindione","drug":"anisindione","action":"Avoid combination","effect":"May interact with Anisindione","source":"DrugCentral","drugSlug":"anisindione"},{"url":"/drug/apomorphine","drug":"apomorphine","action":"Avoid combination","effect":"May interact with Apomorphine","source":"DrugCentral","drugSlug":"apomorphine"},{"url":"/drug/arsenic-trioxide","drug":"arsenic trioxide","action":"Avoid combination","effect":"May interact with Arsenic Trioxide","source":"DrugCentral","drugSlug":"arsenic-trioxide"},{"url":"/drug/astemizole","drug":"astemizole","action":"Avoid combination","effect":"May interact with Astemizole","source":"DrugCentral","drugSlug":"astemizole"},{"url":"/drug/atazanavir","drug":"atazanavir","action":"Monitor closely","effect":"May interact with Atazanavir So4","source":"DrugCentral","drugSlug":"atazanavir"},{"url":"/drug/atorvastatin","drug":"atorvastatin","action":"Monitor closely","effect":"May interact with Atorvastatin Calcium","source":"DrugCentral","drugSlug":"atorvastatin"},{"url":"/drug/azithromycin","drug":"azithromycin","action":"Avoid combination","effect":"May interact with Azithromycin","source":"DrugCentral","drugSlug":"azithromycin"},{"url":"/drug/chloroquine","drug":"chloroquine","action":"Avoid combination","effect":"May interact with Chloroquine","source":"DrugCentral","drugSlug":"chloroquine"},{"url":"/drug/chlorpromazine","drug":"chlorpromazine","action":"Avoid combination","effect":"May interact with Chlorpromazine","source":"DrugCentral","drugSlug":"chlorpromazine"},{"url":"/drug/ciclosporin","drug":"ciclosporin","action":"Monitor closely","effect":"May interact with Cyclosporine","source":"DrugCentral","drugSlug":"ciclosporin"},{"url":"/drug/ciprofloxacin","drug":"ciprofloxacin","action":"Monitor closely","effect":"May interact with Ciprofloxacin","source":"DrugCentral","drugSlug":"ciprofloxacin"},{"url":"/drug/clarithromycin","drug":"clarithromycin","action":"Avoid combination","effect":"May interact with Clarithromycin","source":"DrugCentral","drugSlug":"clarithromycin"},{"url":"/drug/clotrimazole","drug":"clotrimazole","action":"Avoid combination","effect":"May interact with Clotrimazole","source":"DrugCentral","drugSlug":"clotrimazole"},{"url":"/drug/colchicine","drug":"colchicine","action":"Monitor closely","effect":"May interact with Colchicine","source":"DrugCentral","drugSlug":"colchicine"},{"url":"/drug/dasatinib","drug":"dasatinib","action":"Avoid combination","effect":"May interact with Dasatinib","source":"DrugCentral","drugSlug":"dasatinib"},{"url":"/drug/dextropropoxyphene","drug":"dextropropoxyphene","action":"Avoid combination","effect":"May interact with Propoxyphene","source":"DrugCentral","drugSlug":"dextropropoxyphene"},{"url":"/drug/dicoumarol","drug":"dicoumarol","action":"Avoid combination","effect":"May interact with Dicumarol","source":"DrugCentral","drugSlug":"dicoumarol"}],"commonSideEffects":[{"effect":"Pulmonary infiltrates or fibrosis","drugRate":"reported","severity":"serious"},{"effect":"Paroxysmal ventricular tachycardia","drugRate":"reported","severity":"serious"},{"effect":"Congestive heart failure","drugRate":"reported","severity":"serious"},{"effect":"Elevation of liver enzymes","drugRate":"reported","severity":"serious"},{"effect":"Visual disturbances","drugRate":"reported","severity":"serious"},{"effect":"Solar dermatitis","drugRate":"reported","severity":"mild"},{"effect":"Blue skin discoloration","drugRate":"reported","severity":"mild"},{"effect":"Hyperthyroidism","drugRate":"reported","severity":"mild"},{"effect":"Hypothyroidism","drugRate":"reported","severity":"mild"},{"effect":"Nausea and vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dermatologic: Solar dermatitis/photosensitivity","drugRate":"15%","severity":"common","_validated":true},{"effect":"Bradycardia","drugRate":"reported","severity":"serious"},{"effect":"Malaise and fatigue","drugRate":"reported","severity":"mild"},{"effect":"Tremor/abnormal involuntary movements","drugRate":"reported","severity":"mild"},{"effect":"Lack of coordination","drugRate":"reported","severity":"mild"},{"effect":"Abnormal gait/ataxia","drugRate":"reported","severity":"mild"},{"effect":"Dizziness","drugRate":"reported","severity":"mild"},{"effect":"Paresthesias","drugRate":"reported","severity":"mild"},{"effect":"Constipation","drugRate":"reported","severity":"mild"},{"effect":"Anorexia","drugRate":"reported","severity":"mild"},{"effect":"Hypotension","drugRate":"reported","severity":"serious"},{"effect":"Sinus arrest","drugRate":"reported","severity":"serious"},{"effect":"Anaphylactic/anaphylactoid reaction","drugRate":"reported","severity":"serious"}],"contraindications":["Bradycardia","Breastfeeding (mother)","Cardiogenic shock","Chronic heart failure","Chronic lung disease","Complete atrioventricular block","Congenital long QT syndrome","Corneal deposit","Disease of liver","Disorder of optic nerve","Drug-induced hepatitis","Eosinophilic asthma","Extrinsic allergic alveolitis","Hyperthyroidism","Hypokalemia","Hypomagnesemia","Hypothyroidism","Interstitial pneumonia","Liver function tests abnormal","Optic neuritis","Peripheral nerve disease","Pregnancy, function","Prolonged QT interval","Pulmonary hemorrhage","Refractive keratoplasty by laser surgery"],"specialPopulations":{"Lactation":"There are cases of hypothyroidism and bradycardia in breastfed infants, although it is unclear if these effects are due to amiodarone exposure in breastmilk. Breastfeeding is not recommended during treatment with amiodarone hydrochloride.","Pregnancy":"Use amiodarone during pregnancy only if the potential benefit to the mother justifies the risk to the fetus. Reported risks include: neonatal bradycardia, QT prolongation, and periodic ventricular extrasystoles; neonatal hypothyroidism (with or without goiter) detected antenatally or in the newborn and reported even after few days of exposure; neonatal hyperthyroxinemia; neurodevelopmental abnormalities independent of thyroid function, including speech delay and difficulties with written language.","Geriatric use":"Clinical studies of amiodarone hydrochloride tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases and drug therapy.","Paediatric use":"The safety and effectiveness of amiodarone hydrochloride tablets in pediatric patients have not been established."},"discontinuationRates":[{"trial":"","drugArm":"7% to 18%","placeboArm":"","commonReason":"pulmonary toxicity, paroxysmal ventricular tachycardia, congestive heart failure, and elevation of liver enzymes"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.7910/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$289","description":"AMIODARONE HCL 100 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMIODARONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:32:50.832512+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:32:56.572724+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:32:49.967620+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMIODARONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:32:56.858454+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:32:45.891113+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: PULMONARY, HEPATIC and CARDIAC TOXICITY Pacerone is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity [see Indications and Usage (1) ] . Pacerone can cause pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 17% in some series of patients. Pulmonary toxicity has been fatal about 10% of the time . Ob","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:32:45.891146+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. One of its main effects, with prolonged administration, is to lengthen the cardiac action potential, a class III effect. The negative chronotropic effect of ami","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:39.291392+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: HERG blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:32:57.925943+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1083993/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:32:57.580400+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious adverse reactions are described in more detail in other sections of the prescribing information: Pulmonary Toxicity [see Warnings and Precautions (5.2) ] Hepatic Injury [see Warnings and Precautions (5.3) ] Worsened Arrhythmia [see Warnings and Precautions (5.4) ] Visual Impairment and Loss of Vision [see Warnings and Precautions (5.5) ] Thyroid Abnormalities [see Warnings and Precautions (5.6) ] Bradycardia [see Warnings and Precautions (5.7) ] Peripher","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:45.144194+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA075135","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:32:45.891151+00:00"}},"allNames":"cordarone","offLabel":[],"synonyms":["amiodarone","amidorone","sedacoron","amiodarone hydrochloride","amiodarone HCl"],"timeline":[{"date":"1985-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from WYETH PHARMS INC to Wyeth Pharms Inc"},{"date":"1985-12-24","type":"positive","source":"DrugCentral","milestone":"FDA approval (Wyeth Pharms Inc)"},{"date":"2004-02-04","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Intl Medication Sys)"},{"date":"2005-04-12","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 16 manufacturers approved"},{"date":"2008-12-24","type":"positive","source":"FDA Orange Book","milestone":"Nexterone approved — 50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"}],"aiSummary":"Cordarone (Amiodarone) is a small molecule antiarrhythmic medication originally developed by Wyeth Pharms Inc and currently owned by the same company. It targets 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase and is FDA-approved for the treatment of life-threatening ventricular tachycardia, prevention of ventricular fibrillation, and ventricular fibrillation. Cordarone is off-patent and has multiple generic manufacturers. Key safety considerations include its long half-life of 820 hours and bioavailability of 50%. It is essential to monitor patients for potential side effects, such as thyroid dysfunction and pulmonary fibrosis.","brandName":"Cordarone","ecosystem":[{"indication":"Life-Threatening Ventricular Tachycardia","otherDrugs":[{"name":"bretylium","slug":"bretylium","company":"Intl Medication"},{"name":"flecainide","slug":"flecainide","company":""},{"name":"procainamide","slug":"procainamide","company":""},{"name":"procaine","slug":"procaine","company":"Lederle"}],"globalPrevalence":null},{"indication":"Prevention of Ventricular Fibrillation","otherDrugs":[{"name":"bretylium","slug":"bretylium","company":"Intl Medication"}],"globalPrevalence":null},{"indication":"Ventricular fibrillation","otherDrugs":[{"name":"bretylium","slug":"bretylium","company":"Intl Medication"}],"globalPrevalence":null}],"mechanism":{"target":"sodium channels, potassium channels, calcium channels","novelty":"Follow-on","targets":[{"gene":"EBP","source":"DrugCentral","target":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase","protein":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"SCN5A","source":"DrugCentral","target":"Sodium channel protein type 5 subunit alpha","protein":"Sodium channel protein type 5 subunit alpha"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"}],"moaClass":"Cytochrome P450 1A2 Inhibitors","modality":"Small molecule","drugClass":"Antiarrhythmic","explanation":"Amiodarone works by affecting the electrical activity of the heart. It blocks various ion channels, which helps to stabilize heart rhythms by slowing down the conduction of electrical signals and making the heart less likely to beat irregularly. Additionally, it dilates blood vessels, reducing the workload on the heart and lowering oxygen demand.","oneSentence":"Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects.","technicalDetail":"Amiodarone blocks sodium channels at rapid pacing frequencies, similar to class I drugs, and exerts a noncompetitive antisympathetic action like class II drugs. It also prolongs the cardiac action potential, a class III effect, and has a negative chronotropic effect in nodal tissues similar to class IV drugs. It blocks myocardial potassium channels, contributing to slowing of conduction and prolongation of refractoriness. The antisympathetic action and block of calcium and potassium channels are responsible for the negative dromotropic effects on the sinus node and AV node. It prolongs the duration of the action potential in all cardiac fibers and increases the cardiac refractory period without significantly affecting resting membrane potential, except in automatic cells where it reduces the slope of the prepotential, generally reducing automaticity."},"commercial":{"launchDate":"1985","_launchSource":"DrugCentral (FDA 1985-12-24, WYETH PHARMS INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/176","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMIODARONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMIODARONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:43:44.569697","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:33:48.445509+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bretylium","drugSlug":"bretylium","fdaApproval":"1986-03-06","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dofetilide","drugSlug":"dofetilide","fdaApproval":"1999-10-01","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ibutilide","drugSlug":"ibutilide","fdaApproval":"1995-12-28","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dronedarone","drugSlug":"dronedarone","fdaApproval":"2009-07-01","patentExpiry":"Jun 30, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"amiodarone","indications":{"approved":[{"name":"Life-Threatening Ventricular Tachycardia","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients refractory to other therapy"},{"name":"Prevention of Ventricular Fibrillation","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"no specific eligibility criteria mentioned"},{"name":"Ventricular fibrillation","source":"DrugCentral","snomedId":71908006,"regulator":"FDA","eligibility":"no specific eligibility criteria mentioned"}],"offLabel":[{"name":"Atrial fibrillation","source":"DrugCentral","drugName":"AMIODARONE","evidenceCount":3377,"evidenceLevel":"strong"},{"name":"Cardioversion of Atrial Fibrillation","source":"DrugCentral","drugName":"AMIODARONE","evidenceCount":818,"evidenceLevel":"strong"},{"name":"Prevention of Post Cardio-Thoracic Surgery Atrial Fibrillation","source":"DrugCentral","drugName":"AMIODARONE","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Wyeth Pharms Inc","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"bretylium","brandName":"bretylium","genericName":"bretylium","approvalYear":"1986","relationship":"same-class"},{"drugId":"dofetilide","brandName":"dofetilide","genericName":"dofetilide","approvalYear":"1999","relationship":"same-class"},{"drugId":"ibutilide","brandName":"ibutilide","genericName":"ibutilide","approvalYear":"1995","relationship":"same-class"},{"drugId":"dronedarone","brandName":"dronedarone","genericName":"dronedarone","approvalYear":"2009","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06669299","phase":"NA","title":"Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies","status":"RECRUITING","sponsor":"IRCCS Ospedale San Raffaele","startDate":"2025-06-12","conditions":["Ventricular Tachycardia (VT)"],"enrollment":51,"completionDate":"2027-12"},{"nctId":"NCT07487714","phase":"PHASE4","title":"Comparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration","status":"ENROLLING_BY_INVITATION","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2026-01-12","conditions":["Paroxysmal AF","Treatment Decisions","Therapeutic Drug Monitoring (TDM)"],"enrollment":80,"completionDate":"2027-08"},{"nctId":"NCT05034432","phase":"PHASE4","title":"The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2022-05-27","conditions":["Arrythmia","Cardiomyopathies"],"enrollment":100,"completionDate":"2027-06-30"},{"nctId":"NCT05543278","phase":"PHASE4","title":"Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-01","conditions":["Surgery, Cardiac","Atrial Fibrillation"],"enrollment":0,"completionDate":"2027-12"},{"nctId":"NCT05524077","phase":"NA","title":"Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Western Sydney Local Health District","startDate":"2020-07-08","conditions":["Heart Disease Structural Disorder","Ventricular Tachycardia","Cardiomyopathy, Dilated","Sarcoidosis","Cardiomyopathy, Hypertrophic","Cardiomyopathy Ischemic","Cardiomyopathy, Familial","Arrhythmogenic Right Ventricular Cardiomyopathy 1","Arrhythmogenic Left Ventricular Cardiomyopathy"],"enrollment":162,"completionDate":"2026-06-30"},{"nctId":"NCT03842020","phase":"NA","title":"Pharmacokinetics of Amiodarone in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-02-13","conditions":["Heart Rhythm Disorder"],"enrollment":57,"completionDate":"2020-12-12"},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":["Acute Aluminum Phosphide Poisoned Cases"],"enrollment":74,"completionDate":"2027-03"},{"nctId":"NCT07447297","phase":"NA","title":"Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-01-02","conditions":["Atrial Fibrillation (AF)","Diseases of the Circulatory System","Atrial Flutter"],"enrollment":520,"completionDate":"2029-12-31"},{"nctId":"NCT06096337","phase":"NA","title":"Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2023-12-28","conditions":["Persistent Atrial Fibrillation"],"enrollment":484,"completionDate":"2028-02-04"},{"nctId":"NCT06063538","phase":"EARLY_PHASE1","title":"Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-02-15","conditions":["Atrial Fibrillation","Post-Op Complication"],"enrollment":63,"completionDate":"2027-06"},{"nctId":"NCT03868150","phase":"PHASE4","title":"Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment","status":"RECRUITING","sponsor":"Stanford University","startDate":"2017-03-01","conditions":["Postoperative Atrial Fibrillation"],"enrollment":600,"completionDate":"2050-12-31"},{"nctId":"NCT07405671","phase":"PHASE4","title":"Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-09","conditions":["Atrial Fibrillation (AF)","Coronary Artery Disease"],"enrollment":988,"completionDate":"2029-12"},{"nctId":"NCT04239144","phase":"NA","title":"Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2018-11-09","conditions":["Chagas Cardiomyopathy","Ventricular Arrythmia"],"enrollment":45,"completionDate":"2025-12-12"},{"nctId":"NCT07396506","phase":"NA","title":"Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2023-06-05","conditions":["Atrial Fibrillation (AF)"],"enrollment":51,"completionDate":"2023-07-10"},{"nctId":"NCT07396519","phase":"NA","title":"Bioequivalence Study of Dronedarone Hydrochloride Tablets","status":"COMPLETED","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-11-14","conditions":["Atrial Fibrillation (AF)"],"enrollment":48,"completionDate":"2022-12-07"},{"nctId":"NCT04594746","phase":"PHASE4","title":"Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2022-02-03","conditions":["Atrial Fibrillation"],"enrollment":3,"completionDate":"2026-01-20"},{"nctId":"NCT03856632","phase":"PHASE4","title":"Liraglutide Effect in Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2019-03-18","conditions":["Atrial Fibrillation"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT05790707","phase":"NA","title":"EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2023-04-21","conditions":["Mild Cognitive Impairment","Persistent Atrial Fibrillation"],"enrollment":120,"completionDate":"2027-07"},{"nctId":"NCT04844801","phase":"NA","title":"Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-11-09","conditions":["Supraventricular Arrhythmia","Septic Shock"],"enrollment":240,"completionDate":"2026-03"},{"nctId":"NCT07313605","phase":"PHASE1,PHASE2","title":"POCUS-Guided Esmolol in Septic Shock: A Pilot RCT","status":"NOT_YET_RECRUITING","sponsor":"John Basmaji","startDate":"2026-01-15","conditions":["Septic Shock"],"enrollment":100,"completionDate":"2028-04-15"},{"nctId":"NCT06835491","phase":"PHASE3","title":"Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm","status":"RECRUITING","sponsor":"Versailles Hospital","startDate":"2025-11-06","conditions":["Ventricular Arrhythmias and Cardiac Arrest"],"enrollment":674,"completionDate":"2027-03-15"},{"nctId":"NCT07270848","phase":"PHASE4","title":"Dronedarone Rhythm Intervention for Early Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Inha University Hospital","startDate":"2026-01-01","conditions":["Atrial Fibrillation (AF)"],"enrollment":1898,"completionDate":"2028-12"},{"nctId":"NCT06680869","phase":"PHASE3","title":"Early Amiodarone in Shockable Cardiac Arrest","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2025-01-01","conditions":["Cardiac Arrest"],"enrollment":585,"completionDate":"2028-01-31"},{"nctId":"NCT07273994","phase":"PHASE4","title":"Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2025-11-01","conditions":["Persistent Atrial Fibrillation"],"enrollment":312,"completionDate":"2028-04"},{"nctId":"NCT06722196","phase":"PHASE3","title":"BiodEgradable Soaked Amiodarone paTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery","status":"RECRUITING","sponsor":"Jilin Heart Hospital","startDate":"2025-02-15","conditions":["Atrial Fibrillation (AF)"],"enrollment":500,"completionDate":"2027-12-15"},{"nctId":"NCT05780320","phase":"","title":"A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2022-09-19","conditions":["Atrial Fibrillation New Onset"],"enrollment":242,"completionDate":"2025-03-15"},{"nctId":"NCT07236398","phase":"","title":"Modified Left Atrial Maze Procedure for Concomitant AF Ablation","status":"ENROLLING_BY_INVITATION","sponsor":"University Paul Sabatier of Toulouse","startDate":"2023-06-08","conditions":["Atrial Fibrillation","Cardiac Arrhythmia"],"enrollment":151,"completionDate":"2025-12-15"},{"nctId":"NCT07238452","phase":"PHASE4","title":"Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12-01","conditions":["Heart Failure With Reduced Ejection Fraction","Atrial Fibrillation (AF)"],"enrollment":1056,"completionDate":"2033-01-01"},{"nctId":"NCT04316611","phase":"PHASE2","title":"Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-12","conditions":["Out-of-hospital Cardiac Arrest (OHCA)"],"enrollment":0,"completionDate":"2024-12"},{"nctId":"NCT04837261","phase":"","title":"Shortening Duration of Antiarrhythmic Medication for SVT in Infants","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2021-04-15","conditions":["Supraventricular Tachycardia"],"enrollment":107,"completionDate":"2024-01-31"},{"nctId":"NCT04704050","phase":"PHASE4","title":"Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence","status":"TERMINATED","sponsor":"Tulane University School of Medicine","startDate":"2021-05-15","conditions":["Atrial Fibrillation","Atrial Fibrillation Recurrent"],"enrollment":22,"completionDate":"2022-12-20"},{"nctId":"NCT06067438","phase":"PHASE2","title":"Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-06-21","conditions":["Atrial Fibrillation","Esophageal Carcinoma"],"enrollment":90,"completionDate":"2026-08-30"},{"nctId":"NCT07181265","phase":"PHASE1","title":"Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2025-10-30","conditions":["Autosomal Dominant Polycystic Kidney Disease (ADPKD)"],"enrollment":48,"completionDate":"2026-06-30"},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":["Atrial Fibrillation","Stroke"],"enrollment":100,"completionDate":"2027-06"},{"nctId":"NCT06553391","phase":"","title":"Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2024-08-01","conditions":["Atrial Fibrillation"],"enrollment":106,"completionDate":"2025-05-30"},{"nctId":"NCT07130175","phase":"NA","title":"Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)","status":"COMPLETED","sponsor":"Qian Feng","startDate":"2022-12-31","conditions":["Polymorphic Ventricular Tachycardia","Heart Failure"],"enrollment":118,"completionDate":"2024-12-31"},{"nctId":"NCT05841056","phase":"PHASE3","title":"Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2024-06-13","conditions":["Atrial Fibrillation New Onset"],"enrollment":400,"completionDate":"2026-09-30"},{"nctId":"NCT06963203","phase":"","title":"Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis","status":"RECRUITING","sponsor":"Andrea Goldmann","startDate":"2025-07-01","conditions":["Graves Disease","Amiodarone-Induced Thyrotoxicosis","Thyroidectomy"],"enrollment":486,"completionDate":"2027-12"},{"nctId":"NCT05549752","phase":"PHASE3","title":"Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia","status":"RECRUITING","sponsor":"Hippocration General Hospital","startDate":"2023-03-24","conditions":["Atrial Fibrillation Paroxysmal","Coronary Artery Disease Without Residual Ischemia"],"enrollment":80,"completionDate":"2026-01-30"},{"nctId":"NCT06789588","phase":"PHASE3","title":"Protocol for Improvement of Therapy With Warfarin","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pernambuco","startDate":"2024-10-21","conditions":["Atrial Fibrillation (AF)"],"enrollment":700,"completionDate":"2027-07"},{"nctId":"NCT06699342","phase":"NA","title":"Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-01-27","conditions":["Atrial Fibrillation (AF)"],"enrollment":50,"completionDate":"2027-12-31"},{"nctId":"NCT02750319","phase":"PHASE3","title":"Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-04","conditions":["Thoracic Surgery","Atrial Fibrillation in High Risk Patients"],"enrollment":184,"completionDate":"2026-04"},{"nctId":"NCT06322017","phase":"NA","title":"Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-09","conditions":["Atrial Fibrillation"],"enrollment":294,"completionDate":"2030-04-09"},{"nctId":"NCT06930599","phase":"NA","title":"Circumferential Pulmonary Vein Isolation Plus Transition Zone Modification in Atrial Fibrillation Patients Without Low-Voltage Areas","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-09","conditions":["Atrial Fibrillation (AF)"],"enrollment":162,"completionDate":"2026-10-09"},{"nctId":"NCT05445297","phase":"PHASE4","title":"Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter","status":"COMPLETED","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2022-01-26","conditions":["Atrial Fibrillation Paroxysmal"],"enrollment":60,"completionDate":"2023-06-30"},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT06030141","phase":"NA","title":"Investigation of the Effect of Nigella Sativa Oil and Sesame Oil in Preventing Phlebitis","status":"COMPLETED","sponsor":"Kutahya Health Sciences University","startDate":"2023-11-15","conditions":["Phlebitis","Peripheral Venous Catheterization"],"enrollment":108,"completionDate":"2024-10-01"},{"nctId":"NCT00540787","phase":"PHASE4","title":"A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation","status":"COMPLETED","sponsor":"Biosense Webster, Inc.","startDate":"2003-08-01","conditions":["Paroxysmal Atrial Fibrillation"],"enrollment":112,"completionDate":"2006-06-01"},{"nctId":"NCT06817447","phase":"NA","title":"Pulmonary Vein Isolation in Typical Atrial Flutter and Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-03-01","conditions":["Atrial Flutter Typical","Heart Failure"],"enrollment":168,"completionDate":"2029-03-01"},{"nctId":"NCT00227344","phase":"PHASE4","title":"CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation","status":"TERMINATED","sponsor":"Biosense Webster EMEA","startDate":"2004-12","conditions":["Atrial Fibrillation"],"enrollment":129,"completionDate":"2009-05"},{"nctId":"NCT05130268","phase":"PHASE4","title":"Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation","status":"COMPLETED","sponsor":"American Heart Association","startDate":"2021-10-29","conditions":["Atrial Fibrillation"],"enrollment":339,"completionDate":"2024-06-30"},{"nctId":"NCT06262932","phase":"PHASE4","title":"Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response","status":"COMPLETED","sponsor":"Police General Hospital, Thailand","startDate":"2024-05-01","conditions":["Atrial Fibrillation"],"enrollment":24,"completionDate":"2024-12-31"},{"nctId":"NCT05391893","phase":"PHASE4","title":"Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation","status":"COMPLETED","sponsor":"Corewell Health South","startDate":"2020-06-19","conditions":["Atrial Fibrillation","Atrial Flutter"],"enrollment":444,"completionDate":"2023-04-01"},{"nctId":"NCT06742866","phase":"NA","title":"Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-12-16","conditions":["Atrial Fibrillation (AF)"],"enrollment":418,"completionDate":"2026-07-01"},{"nctId":"NCT06730828","phase":"PHASE1,PHASE2","title":"Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects","status":"RECRUITING","sponsor":"Helios Cardio Inc.","startDate":"2024-12-16","conditions":["Atrial Fibrillation, Postoperative"],"enrollment":80,"completionDate":"2026-05"},{"nctId":"NCT06645249","phase":"PHASE4","title":"Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Institut Investigacio Sanitaria Pere Virgili","startDate":"2024-12-10","conditions":["Atrial Fibrillation (AF)"],"enrollment":122,"completionDate":"2026-10"},{"nctId":"NCT06710600","phase":"NA","title":"Phototoxicity of Frequently Prescribed Medicines","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2022-09-22","conditions":["Phototoxicity"],"enrollment":12,"completionDate":"2024-10-03"},{"nctId":"NCT04037397","phase":"PHASE3","title":"First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-09-24","conditions":["Atrial Fibrillation"],"enrollment":25,"completionDate":"2024-10-01"},{"nctId":"NCT06657404","phase":"NA","title":"The Modified \"Pills-in-the-Pocket\" Strategy","status":"RECRUITING","sponsor":"Yumei Xue","startDate":"2024-10-23","conditions":["Atrial Fibrillation (AF)"],"enrollment":328,"completionDate":"2024-12-31"},{"nctId":"NCT06632925","phase":"","title":"Utility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Software: a Prospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2024-10-01","conditions":["Atrial Fibrillation (AF)"],"enrollment":80,"completionDate":"2027-06-30"},{"nctId":"NCT02459574","phase":"NA","title":"Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-05-01","conditions":["Heart Failure","Recurrent Atrial Fibrillation"],"enrollment":321,"completionDate":"2018-11-27"},{"nctId":"NCT06560047","phase":"NA","title":"Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure","status":"RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2024-08-28","conditions":["Atrial Fibrillation","Heart Failure"],"enrollment":1616,"completionDate":"2039-08-31"},{"nctId":"NCT06556732","phase":"PHASE1","title":"Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease","status":"RECRUITING","sponsor":"Assiut University","startDate":"2024-08-10","conditions":["Atrial Fibrillation"],"enrollment":100,"completionDate":"2024-08-31"},{"nctId":"NCT01422148","phase":"PHASE2","title":"Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Baystate Medical Center","startDate":"2025-07","conditions":["Atrial Fibrillation"],"enrollment":60,"completionDate":"2028-01-24"},{"nctId":"NCT02830360","phase":"PHASE4","title":"Antiarrhythmics or Ablation for Ventricular Tachycardia 2","status":"COMPLETED","sponsor":"John Sapp","startDate":"2016-10","conditions":["Ventricular Tachycardia (VT)"],"enrollment":416,"completionDate":"2024-06-30"},{"nctId":"NCT05169866","phase":"PHASE3","title":"Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2022-05-29","conditions":["New Onset Atrial Fibrillation","Complications; Cardiac, Postoperative"],"enrollment":274,"completionDate":"2025-06"},{"nctId":"NCT04748991","phase":"PHASE3","title":"Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2024-09","conditions":["Atrial Fibrillation","Post-cardiac Surgery"],"enrollment":50,"completionDate":"2025-09"},{"nctId":"NCT06394466","phase":"","title":"Thyroid Function and Autoimmunity in Subfertility Women and Assisted Reproductive Therapy","status":"COMPLETED","sponsor":"Rio de Janeiro State University","startDate":"2021-07-01","conditions":["Ovarian Failure","Thyroid Diseases"],"enrollment":453,"completionDate":"2023-07-31"},{"nctId":"NCT04942834","phase":"NA","title":"Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-10-01","conditions":["Atrial Fibrillation, Persistent","Arrhythmias, Cardiac"],"enrollment":286,"completionDate":"2026-01"},{"nctId":"NCT05287191","phase":"PHASE3","title":"MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-01-05","conditions":["Atrial Fibrillation New Onset"],"enrollment":200,"completionDate":"2026-04-30"},{"nctId":"NCT05058053","phase":"NA","title":"THE EFFECT OF COLD APPLICATION ON THE DEVELOPMENT OF PHLEBITIS IN PATIENTS RECEIVING INTRAVENOUS AMIODARONE TREATMENT.","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2020-03-01","conditions":["Phlebitis"],"enrollment":100,"completionDate":"2021-03-01"},{"nctId":"NCT04168970","phase":"","title":"Percutaneous Left Stellate Ganglion Block In Out-of-hospital Cardiac Arrest Due to Refractory VEntricular Arrhythmias (LIVE Study)","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2019-07-15","conditions":["Out-Of-Hospital Cardiac Arrest","Ventricular Fibrillation Sustained"],"enrollment":53,"completionDate":"2025-07-31"},{"nctId":"NCT04997980","phase":"","title":"AMSA and Amiodarone Study in Cardiac Arrest","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2015-01-01","conditions":["Out-Of-Hospital Cardiac Arrest"],"enrollment":629,"completionDate":"2023-12-31"},{"nctId":"NCT05681182","phase":"PHASE4","title":"Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone","status":"COMPLETED","sponsor":"WakeMed Health and Hospitals","startDate":"2023-01-20","conditions":["Post Operative Atrial Fibrillation"],"enrollment":30,"completionDate":"2024-02-06"},{"nctId":"NCT05279833","phase":"","title":"Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-09-24","conditions":["Atrial Fibrillation"],"enrollment":87810,"completionDate":"2022-03-31"},{"nctId":"NCT05293080","phase":"PHASE3","title":"Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE","status":"NOT_YET_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2024-09","conditions":["Acute Ischemic Stroke","Atrial Fibrillation"],"enrollment":1746,"completionDate":"2029-03"},{"nctId":"NCT06168994","phase":"PHASE4","title":"Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-02-01","conditions":["Paroxysmal Atrial Fibrillation"],"enrollment":100,"completionDate":"2027-05-20"},{"nctId":"NCT06125925","phase":"NA","title":"Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-11-06","conditions":["Atrial Fibrillation","HFpEF - Heart Failure With Preserved Ejection Fraction"],"enrollment":436,"completionDate":"2026-11"},{"nctId":"NCT05326568","phase":"NA","title":"Effect of Sesame Oil in Preventing Phlebitis","status":"COMPLETED","sponsor":"Cukurova University","startDate":"2023-06-15","conditions":["Phlebitis After Infusion"],"enrollment":44,"completionDate":"2023-10-15"},{"nctId":"NCT05004077","phase":"PHASE4","title":"Repeated Amiodarone Dosing In Cardiac surgicaL Procedures","status":"TERMINATED","sponsor":"Kevin W Hatton, MD, PhD","startDate":"2021-11-02","conditions":["Atrial Fibrillation"],"enrollment":3,"completionDate":"2022-10-10"},{"nctId":"NCT01742039","phase":"","title":"Prevention of Postoperative Atrial Fibrillation","status":"COMPLETED","sponsor":"George Washington University","startDate":"2008-07","conditions":["Postoperative Atrial Fibrillation"],"enrollment":160,"completionDate":"2011-06"},{"nctId":"NCT05993897","phase":"NA","title":"Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling","status":"UNKNOWN","sponsor":"Aswan University","startDate":"2023-08","conditions":["Atrial Fibrillation"],"enrollment":60,"completionDate":"2024-12"},{"nctId":"NCT01229254","phase":"PHASE2","title":"Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2010-09","conditions":["Atrial Fibrillation","Atrial Flutter"],"enrollment":189,"completionDate":"2011-04"},{"nctId":"NCT02389218","phase":"PHASE4","title":"A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2015-03-03","conditions":["Atrial Fibrillation"],"enrollment":13,"completionDate":"2020-05-14"},{"nctId":"NCT05950971","phase":"NA","title":"Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2021-07-01","conditions":["Atrial Fibrillation New Onset","Atrial Fibrillation Paroxysmal"],"enrollment":1,"completionDate":"2022-01-21"},{"nctId":"NCT05364866","phase":"","title":"CAB Versus Medical Therapy in Patients With AF and HF With Different EF Categories","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-05-01","conditions":["Cardiovascular Diseases"],"enrollment":200,"completionDate":"2024-12-31"},{"nctId":"NCT05655468","phase":"PHASE4","title":"Effect of Prolonged Use of Dronedarone on Recurrence in Patients With Non-paroxysmal Atrial Fibrillation After Radiofrequency Ablation","status":"UNKNOWN","sponsor":"Shanghai East Hospital","startDate":"2023-03-29","conditions":["Atrial Fibrillation"],"enrollment":268,"completionDate":"2025-11"},{"nctId":"NCT03531502","phase":"NA","title":"Initial Management of Patients Receiving a Single Shock (IMPRESS)","status":"TERMINATED","sponsor":"Saint Luke's Health System","startDate":"2018-04-09","conditions":["Ventricular Tachycardia"],"enrollment":30,"completionDate":"2023-04-04"},{"nctId":"NCT04392921","phase":"NA","title":"Prophylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-03-07","conditions":["Atrial Fibrillation"],"enrollment":80,"completionDate":"2024-04"},{"nctId":"NCT05641883","phase":"NA","title":"CardiaMend and Amiodarone for the Prevention of POAF","status":"UNKNOWN","sponsor":"Saint Alphonsus Regional Medical Center","startDate":"2023-01-01","conditions":["POAF","Atrial Fibrillation"],"enrollment":30,"completionDate":"2023-05-31"},{"nctId":"NCT04208997","phase":"PHASE3","title":"Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-12-19","conditions":["Tachycardia, Ventricular","Catheter Ablation"],"enrollment":5,"completionDate":"2021-06-30"},{"nctId":"NCT02825979","phase":"NA","title":"Early Aggressive Invasive Intervention for Atrial Fibrillation","status":"UNKNOWN","sponsor":"Jason Andrade","startDate":"2017-01","conditions":["Atrial Fibrillation"],"enrollment":303,"completionDate":"2022-11"},{"nctId":"NCT03029169","phase":"PHASE4","title":"Propafenone Versus Amiodarone in Septic Shock","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2017-10-23","conditions":["Supraventricular Arrhythmia","Septic Shock"],"enrollment":210,"completionDate":"2022-08-01"},{"nctId":"NCT03437356","phase":"NA","title":"Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drugs in Persistent Atrial Fibrillation","status":"COMPLETED","sponsor":"AZ Sint-Jan AV","startDate":"2018-02-26","conditions":["Atrial Fibrillation"],"enrollment":210,"completionDate":"2022-06-30"},{"nctId":"NCT04542785","phase":"NA","title":"Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation Randomised Clinical Trial","status":"UNKNOWN","sponsor":"Holbaek Sygehus","startDate":"2021-03-31","conditions":["Atrial Fibrillation, Persistent","Atrial Fibrillation Chronic","Atrial Fibrillation"],"enrollment":350,"completionDate":"2026-03-02"},{"nctId":"NCT04234906","phase":"PHASE4","title":"Prevention of Post-Operative Cardiac Arrhythmias","status":"UNKNOWN","sponsor":"Jeffrey Moak","startDate":"2023-01","conditions":["Cardiac; Dysrhythmia, Postoperative","Congenital Heart Surgery"],"enrollment":870,"completionDate":"2023-08"},{"nctId":"NCT01416935","phase":"NA","title":"Necessity of Anti-Arrhythmic Medication After Surgical Ablation for Atrial Fibrillation","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2011-01-01","conditions":["Atrial Fibrillation"],"enrollment":186,"completionDate":"2016-07"},{"nctId":"NCT05125042","phase":"NA","title":"Catgut Embedding in Acupoints on Treating Persistent Atrial Fibrillation After Catheter Ablation","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2021-12-01","conditions":["Persistent Atrial Fibrillation"],"enrollment":120,"completionDate":"2023-12-20"},{"nctId":"NCT03720210","phase":"NA","title":"Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-11-19","conditions":["Amiodarone-Induced Thyrotoxicosis"],"enrollment":1,"completionDate":"2020-12-07"},{"nctId":"NCT04351763","phase":"PHASE2,PHASE3","title":"Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","status":"COMPLETED","sponsor":"Nicolaus Copernicus University","startDate":"2020-05-20","conditions":["COVID-19"],"enrollment":804,"completionDate":"2021-06-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection, Tablet","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Amiodarone Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"AMIODARONE HCI"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"AMIODARONE HYDROCHLORIDE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Amiodarone Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Amiodarone hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"amiodarone hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"NEXTERONE (AMIODARONE HCI)"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Nexterone"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Amiodarone HCl"},{"form":"TABLET","route":"ORAL","productName":"Amiodarone HCl"},{"form":"TABLET","route":"ORAL","productName":"Amiodarone Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"Amiodarone hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"PACERONE"},{"form":"TABLET","route":"ORAL","productName":"Pacerone"},{"form":"TABLET","route":"ORAL","productName":"amiodarone hydrochloride"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147701","MMSL":"13960","NDDF":"000629","UNII":"N3RQ532IUT","VUID":"4019606","CHEBI":"CHEBI:2663","VANDF":"4018065","INN_ID":"2012","RXNORM":"203114","UMLSCUI":"C0002598","chemblId":"CHEMBL1083993","ChEMBL_ID":"CHEMBL633","KEGG_DRUG":"D00636","DRUGBANK_ID":"DB01118","PDB_CHEM_ID":"BBI","PUBCHEM_CID":"2157","SNOMEDCT_US":"372821002","IUPHAR_LIGAND_ID":"2566","SECONDARY_CAS_RN":"19774-82-4","MESH_DESCRIPTOR_UI":"D000638"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1985-","companyName":"Pfizer","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"820.0 hours","clearance":"1.9 mL/min/kg","bioavailability":"50%","fractionUnbound":"0.0002%","volumeOfDistribution":"60.0 L/kg"},"publicationCount":11189,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01BD01","allCodes":["C01BD01"]},"biosimilarFilings":[],"originalDeveloper":"Wyeth Pharms Inc","recentPublications":[{"date":"2026 Mar 1","pmid":"41901253","title":"A Simple Dual-Track HPLC-UV Methodology for Monitoring Primary Antiarrhythmic Drugs and Their Active Metabolites in Serum.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 7","pmid":"41896159","title":"Drug-associated torsades de pointes and QT prolongation in infants: A focused real-world disproportionality analysis pharmacovigilance study.","journal":"Pediatrics and neonatology"},{"date":"2026 Feb 27","pmid":"41892494","title":"Thyroid Monitoring and Amiodarone-Induced Thyroid Disease in Australian General Practice: A Retrospective Cohort Study.","journal":"Clinics and practice"},{"date":"2026 Mar 26","pmid":"41884902","title":"Rapid Atrial Pacing-Induced Wenckebach Atrioventricular Block: A Poor Predictor of Permanent Pacemaker Need Post-TAVR.","journal":"Circulation. Cardiovascular interventions"},{"date":"2026 May","pmid":"41884060","title":"Short- to mid-term outcomes of refractory electrical storm patients listed for urgent heart transplantation.","journal":"JHLT open"}],"companionDiagnostics":[],"genericManufacturers":25,"_genericFilersChecked":true,"genericManufacturerList":["Acella","Aurobindo Pharma Ltd","Bedford","Bedford Labs","Ben Venue","Chartwell Rx","Dr Reddys","Dr Reddys Labs Sa","Epic Pharma Llc","Eugia Pharma","Fresenius Kabi Usa","Gland Pharma Ltd","Hikma Farmaceutica","Hospira","Mylan Institutional","Par Sterile Products","Pharmobedient","Rubicon Research","Taro","Teva","Teva Pharms","Unichem","Upsher Smith Labs","Zhejiang Poly Pharm","Zydus Pharms Usa Inc"],"status":"approved","companyName":"Wyeth Pharms Inc","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1985","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-12-18T00:00:00.000Z","mah":"TARO","brand_name_local":null,"application_number":"ANDA075424"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-05-03T00:00:00.000Z","mah":"DR REDDYS LABS SA","brand_name_local":null,"application_number":"ANDA075389"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-01-15T00:00:00.000Z","mah":"GLAND PHARMA LTD","brand_name_local":null,"application_number":"ANDA077161"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-05-31T00:00:00.000Z","mah":"TARO","brand_name_local":null,"application_number":"ANDA076362"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-10-25T00:00:00.000Z","mah":"EUGIA PHARMA","brand_name_local":null,"application_number":"ANDA204550"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:33:48.445509+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}